1983

The first p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

The clonning “saga”
1983

The first p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

The cloning “saga”
1983

The first p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

The clonning “saga”
1983

The first p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

The clonning “saga”

TIMETABLE

SATURDAY, 7TH MAY 1983

12.00 onwards
Registration at The Research Institute, Treve Hill, Limpsfield Chart, Oxted, Surrey.

BOOK INTO HOTELS

7.00 p.m.
Drinks at The Old Bell, Old Oxted, Surrey.

.8.00 p.m.
Dinner at -ditto-
EVENING FREE.

SUNDAY, 8TH MAY 1983

9.30 a.m.
Workshop at the Research Institute, Limpsfield Chart.

INTRODUCTION

10.00-11.00 a.m.
Morning Session, part 1.

11.10 a.m.
Coffee

11.30-1.00 p.m.
Morning Session, part 2.

1.15 - 2.15 p.m.
Lunch at The Old Bell, Old Oxted.

2.30 - 3.30 p.m.
Afternoon session, part 1.

3.30 - 3.50 p.m.
Tea.

4.00 - 5.30 p.m.
Afternoon Session, part 2.

7.00 p.m.
Drinks

8.00 p.m.
Dinner
EVENING FREE
The first p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

The clonning “saga”
1983

The first p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

The clonning "saga"
1983

The first p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

The clonning “saga”
1987

The second p53 meeting

Centre d’Information Scientifique
De L’A.R.C.
Villejuif
Paris

The p53 genome era
The second p53 meeting

Centre d’Information Scientifique
De L’A.R.C.
Villejuif
Paris

The p53 genome era

---

**INTERNATIONAL WORKSHOP ON P53**

**Wednesday, April 29.**

9:30 a.m. WELCOME       Dr. Pierre MAY

9:45 a.m. INTRODUCTORY REMARKS       Dr. John JENKINS

**SESSION I**

Chairperson: Dr. John JENKINS
Marie Curie Foundation,
Research Institute, OXTED, UK.

Speakers:

10:00 a.m. - Dr. David P. LANE
Imperial Cancer Research Fund, LONDON, UK.

Biochemical effects of p53 on large-T antigen.

10:30 a.m. - Dr. Moshe DREN
Department of Chemical Immunology, REHOVOT, ISRAEL.

Interactions between p53 and heterologous proteins.

11:00 a.m. - Coffee Break

11:45 a.m. - Dr. Arnold J. LEVINE
Department of Molecular Biology, PRINCETON, USA.

Immunological evidence for the association of p53 with a heat shock protein, hsc70 in p53 plus Ras transformed cell lines.

12:15 p.m. - Dr. Horst-Werner STUZBECHER
Marie Curie Foundation, OXTED, UK.

Mutant p53 proteins exhibit diverse targeting capabilities.

12:45 p.m. - LUNCH
1987

The second p53 meeting

Centre d'Information Scientifique De L'A.R.C.
Villejuif
Paris

The p53 genome era

Wednesday, April 29.

SESSION II

Chairperson: Dr. David LANE
Dept. of Biochemistry, LONDON, UK.

Speakers:
2:00 p.m. - Dr. Peter CHUMAKOV
Institute of Molecular Biology, MOSCOW, USSR

2:30 p.m. - Dr. Sam BENCHIMOL
Ontario Cancer Institute, TORONTO, CANADA
Isolation and expression of rearranged p53 genes from murine erythroleukemia.

3:00 p.m. - Dr. Christopher Dale SMITH
Division Cancer Biology and Diagnosis, N.I.H., USA.
Non-complexing of p53 and T Ag in SV40 transformed cells.

3:30 p.m. Coffee Break

4:15 p.m. - Dr. Friedrich GRUMMT
Institute of Biochemistry, ROETGEN RING, FRG.
P53 binds to mammalian origin of replication.

4:45 p.m. - Dr. Jean-Jacques LAWRENCE
Lab. Biologie Moléculaire, INSEERM, GRENOBLE, FRANCE.
p53 accumulation and cell cycle modifications in the induced differentiation of murine Erythro-leukemia cells.
Thursday, April 30.

SESSION III

Chairperson: Dr. Varda ROTTER
Weizmann Institute of Science
REHOVOT, ISRAEL.

Speakers:

9:30 a.m. - Dr. Wolfgang DEPPERT
Department of Biochemistry, ULM, FRG.
Modulation of p53 expression during cellular transformation with SV40.

10:00 a.m. - Dr. Mathias MONTEMARN
Department of Biochemistry, ULM, FRG.
Protein-protein interactions in complexes of simian virus 40 large T antigen and p53.

10:30 a.m. - Dr. Peter T. MORA
National Institutes of Health, BETHESDA, USA.
p53 expression in differentiating systems.

11:00 a.m. - Coffee Break

11:45 a.m. - Dr. Thierry SOUSSI
Unité d’Oncologie Moléculaire, I.R.S.C.,
VILLEJUIF, FRANCE
Non-mammalian p53: characterization and properties.

12:15 p.m. - Dr. Antony BRAITHWAITE
Marie Curie Foundation, OXTED, UK
Stimulation of p53 synthesis during infection of rodent cells with Adeno 5
Thursday, April 30.

SESSION IV

Chairperson: Dr. Moshe OREN
Department of Chemical Immunology,
REHOVOT, ISRAEL.

Speakers:
2:30 p.m. - Dr. Varda ROTTER
Department of Cell Biology, REHOVOT, ISRAEL.
The molecular basis for the heterogeneity of mouse and human p53 protein.

3:00 p.m. - Dr. Jo WILNER
University of Cambridge, CAMBRIDGE, UK.

3:30 p.m. - Coffee Break

4:15 p.m. - Dr. W. Edward MERCER
Department of Pathology, PHILADELPHIA, USA
Growth regulated expression of p53 in normal and malignant human cells.

4:45 p.m. - Dr. Edmond PUVION
Laboratoire de Biologie & Ultrastructure du Noyau,
G.B.G.M., I.R.S.C., VILLEJUIF, FRANCE.
Intranuclear localization of SV40-TAg and p53 in SV40-infected or-transformed cell cultures.

6:00 p.m. - COCKTAIL PARTY
The third p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
The third p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
1988

The third p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
1988

The third p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
1988

The third p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!

Chairperson:

Dr. Varda Rotter
Department of Cell Biology, Weizmann Institute, Rehovot, Israel.

Speakers:

Prof. Wolfgang Deppert
Heinrich-Fette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg, F.R.G.

Prof. Mathias Montenarh
Department of Biochemistry, University of Ulm, F.R.G.

Dr. Varda Rotter
Department of Cell Biology, Weizmann Institute, Rehovot, Israel.

Dr. David Reisman
-ditto-

Mr. Simon Tuck
ICRF Laboratories, London, U.K.
The third p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
1988

The third p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
1988

The third p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Still an ugly duckling!!
We are still very confused!
The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppresser gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
The fourth p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1990

The fourth p53 workshop

The Marie Curie Memorial Foundation Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
The fourth p53 workshop

The Marie Curie Memorial Foundation
Research Institute
The Chart
Oxted, Surrey

Turning into a beautiful Swan!!
Am I tumor Suppressor gene???
1991

The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
1991

The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
1991

The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!
What about K/O mice?
*Transcription factor
*Aptoptosis!!
A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!

What about K/O mice?

*Transcription factor

*Apoptosis!!
The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!

Yew, P.R., and Berk, A.J. Department of Microbiology and Molecular Genetics, University of California, Los Angeles, California "SRK transformation by adenovirus 2 early 19 55K mutants correlates with ability to bind p53" 78

Moolgatke, J.M., Scheffner, M., and Howley, P.M. Laboratory of Tumor Virus Biology, NCI, NIH, Bethesda, Maryland "Complex formation between HPV E6 protein and p53 requires an additional cellular factor" 79

Cheng, J., Yee, J.-K., Yeagren, J., Friedmann, T., and Haas, M. Departments of Pathology, Pediatrics and Biology, University of California Cancer Center, San Diego, California "Suppression of the tumorigenic phenotype of a human acute lymphoblastic leukemia T-cell line by the introduction of a retrovirus construct encoding wild-type p53" 80

Martinez, L., Geogoff, I., Martinez, J., and Levine, A.J. Department of Molecular Biology, Princeton University, Princeton, New Jersey "p53 acts as a negative regulator of cell division: Characterization of a model using the temperature sensitive mutant murine p53" 82

Grunwald, D., Khochbin, S., Lawrence, J.-J. Laboratoire de Biologie Moléculaire du Cycle Cellulaire, INSERM, Grenoble Cedex, France "Cell cycle dependent localization of endogenous p53 in murine erythroblastic leukemia cells" 82

Gervin, R.L.¹, Spellare, E.¹, Forrester, K.¹, Walsh, J.A.¹, Lehman, T.A.¹, Baker, S.J.², Vogelstein, B.², and Harris, C.C.² ¹Laboratory of Human Carcinogenesis, NCI, NIH, Bethesda, Maryland; ²The Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland "Analysis of expression of WT- and Mt-p53 in SV40 T-antigen expressing immortalized human bronchial epithelial cells (BEAS-2B)" 83

Chin, K.-Y.¹, Ueda, K.², Pastan, I.¹, and Gottesman, N.M.¹ ¹Laboratory of Cell Biology and Laboratory of Molecular Biology, NCI, Bethesda, Maryland; ²Department of Agricultural Chemistry, Kyoto University, Kyoto, Japan "Ras and p53 regulate activity of the promoter of the human multidrug resistance gene" 84

Chen, T.-M., and Defendi, V. Department of Pathology, New York University Medical Center, New York, New York "Functional interaction in 3T3 cells of p53 and HPV18 E6, c-myc and H-ras" 85

Beemken, S.W.¹, Karsenty, G.², Raycroft, L.², and Lozano, G.² ¹University of Alabama, Birmingham, Alabama; M.D. Anderson Cancer Center, Houston, Texas "Protein binding of intron 4 is required for p53's transforming ability in vitro" 86
The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!

Newfeld, G., and Peretz, D. Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa, Israel.
"The content of blood in tumors that develop from not transformed cells is correlated inversely with tumor growth rates" 87

Ciechanover, A. 1, DiOtiuseppe, 2, A. 1, Bercovic, B. 1, Gran, A. 1, Richter, J. D. 1, Schwartz, A. L. 2, and Brodew, G. M. 2 *Department of Biochemistry, Faculty of Medicine and the Rapoapart Institute for Research in the Life Sciences, Technion-Israel Institute of Technology, Haifa, Israel; 2Edward Halloway Department of Pediatrics and Division of Hematology-Oncology, Children's Hospital and Washington University School of Medicine, St. Louis, Missouri;
"The ubiquitin system and degradation of nuclear oncoproteins" 88

Bulboy, R.J., and Losesno, G. Department of Molecular Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
"Domain analysis of the transcriptional activator p53" 89

Ronan, D. 1, Reisman, D. 2, and Rotter, Y. 2 1Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Cell Biology, The Weizmann Institute of Science, Rehovot, Israel
"Transcriptional transactivation of p53 protein in transformed cells" 90

SESSION D: p53-DNA Binding
Chair
M. Oren, The Weizmann Institute, Israel
J. Pipes, University of Pittsburgh, Pennsylvania USA

3:30 pm Kern, S.E., Kimzler, K.W., Baker, S.J., Riggs, J.M., Rotter, V., Levine, A.J., Friedman, F., Prives, C., and Vogelstein, B. Oncology Center and Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
"Mutant p53 proteins bind DNA abnormally" 37

Weis'enser, S., Newfeld, A., and Depper, W. Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie, Hamburg, Federal Republic of Germany
"Specific and complex DNA binding properties of mouse p53" 38

Friedman, F., 2 Barghouti, J., 1 Kern, S., 2 Vogelstein, B., and Prives, C. 4Department of Biological Sciences, Columbia University, New York, New York; 2Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD
"Mutant oncogenic p53 proteins differ in structure and function from wild type p53" 39

6 pm Dinner
Forbes College
1991

The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!

What about K/O mice?
*Transcription factor
*Apoptosis!!
A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!

---

The fifth p53 workshop
Princeton University
PRINCETON
USA

---

10:30 am
Break

11 am
Beisner, B., Bore, D., and Rotter, V. Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel
"Site specific binding by c-myc to the p53 promoter: A target for trans-activation by c-myc" 47

Mitchel, S., Minica, P., Dowdy, S., and Weinberg, R.A. Whitehead Institute for Bio-Medical Research, Cambridge, Massachusetts
"Interaction of the retinoblastoma protein with nuclear components" 48

Chen, F.-L., Lee, E., and Lee, Y.-H. Center for Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center, San Antonio, Texas
"Molecular basis of cancer suppression by the human tumor suppressor genes" 49

1 pm
Lunch
Forbes College

SESSION C: p53 Transformation and Negative Growth Regulation
Chair
D. Lane, Dundee University, United Kingdom
T. Souna, Institut de Geneique Moleculaire, France

2 pm
Gimber, D., Michael-Michel-Avitz, D., Yoish-Resem, E., and Green, M. Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel
"Antiproliferative effects of p53: Mechanistic aspects" 50

Hicks, G.R., Parashar, P., Sanders, M., Stewart, N., and Mowar, M. Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Canada
"Negative growth regulation by p53 in transformation" 51

Shaik, D., Goldfinger, N., Peled, A., and Rotter, V. Departments of Cell Biology and Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel
"Wild type p53 expression mediates pre-B cell differentiation" 52
A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance: in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?

*Transcription factor

*Apoptosis!!
1991

The fifth p53 workshop
Princeton University
PRINCETON
USA

A beautiful Swan Indeed!
A bona-fida tumor suppressor!!

*in vivo significance:
in mouse and man!
What about K/O mice?
*Transcription factor
*Apoptosis!!
1992

The Sixth p53 workshop

The Weizmann Institute
Rehovot, Israel

The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be

the

Transcriptional activation

DNA binding

p53 workshop
1-5 November 1992, Tiberias, Israel
1992

The Sixth p53 workshop

The Weizmann Institute
Rehovot, Israel

The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be
1992

The Sixth p53 workshop

The Weizmann Institute
Rehovot, Israel

The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be
1992

The Sixth p53 workshop
The Weizmann Institute
Rehovot, Israel

The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be
The Sixth p53 workshop

The Weizmann Institute
Rehovot, Israel

The Sea of Galilee, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2

The love loop!
To be or not to be
1992

The Sixth p53 workshop

The Weizmann Institute
Rehovot, Israel

The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be
1992

The Sixth p53 workshop
The Weizmann Institute
Rehovot, Israel
The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be

[Session II, continued]
[Session III: Protein-Protein Interactions (1)]
Chair: Wolfgang Deppert and John R. Jenkins

09:00 The functions of the p53 protein
Gerard Zambetti (Princeton) [14]

09:30 A minimal transforming domain of p53: evidence for negative dominance
Moshe Oren (Rehovot) [15]

10:00 Properties of the Mdm-2/p53 complex
Jamil Momand (Princeton) [16]

10:15 The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth
Cathy A. Finlay (Princeton) [17]

10:45 Coffee Break

11:15 Carboxyl tales of p53
Jo Milner (York) [18]

11:45 Regulation of the expression and function of p53
David P. Lane (Dundee) [19]

12:15 Regulation of p53 by phosphorylation
David W. Meek (Dundee) [20]

12:45 Structural and functional aspects of p53 protein from human tumors and tumor cell lines
Matthias Montenarh (Ulm) [21]

13:15 Lunch Break
Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be
1992

The Sixth p53 workshop

The Weizmann Institute
Rehovot, Israel

The Sea of Galille, Israel

Functional Domains!
Finally it makes sense!!

A new partner: mdm2
The love loop!
To be or not to be

12:15 p53 transcriptional autoregulation
Gigi Lozano (Houston) [32]

11:45 Mutant p53 proteins from human cancers exhibit variability in their
transcriptional and DNA binding activities
Tamar Unger (Bethesda) [33]

12:00 Transcriptional regulation by p53
Thomas Shenk (Princeton) [34]

12:30 Wild type p53 can repress transcription initiation in vitro
Yoeli Aloni (Rehovot) [35]

12:45 Lunch Break

Session VI: Cell Cycle and Suppressor Activity
Chair: David Givol and Sam Benichou

14:45 Wild-type p53: a cell cycle checkpoint determinant following irradiation
Michael B. Kastan (Baltimore) [36]

15:15 Genetic regulation of genomic fluidity in normal and neoplastic cells
Thea D. Tlsty (Chapel Hill) [37]

15:30 Expression of the cellular p53 gene in leukemia cells
Sam Benichou (Toronto) [38]

16:00 p53 in progression of chronic myelogenous leukemia
Bil Camasi (Rehovot) [39]

16:15 Coffee Break

16:45 Developmental expression of p53 in Xenopus laevis
Marcel Melech (Paris) [40]

17:00 The role of tumor suppressor genes in normal Xenopus development
Thierry Frisch (Charlestown) [41]

17:20 Use of inhibitory cytokines for isolating and studying tumor suppressor genes
Adi Knecht (Rehovot) [42]

18:00 p53 and RB inhibit cell cycle progression by two distinct pathways
Wen-Hwa Lee (San Antonio) [43]

18:30 POSTER DISCUSSION AND COFFEE

Thursday, November 5

Departure
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

7th p53 Workshop
Program and Abstracts
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Session</td>
<td>Tumor Development and Progression (1)</td>
<td>Chair: Stephen Friend</td>
</tr>
<tr>
<td>8:55</td>
<td></td>
<td>Clinical Implications of Germline p53 Mutations</td>
<td>Stephen Friend</td>
</tr>
<tr>
<td>9:20</td>
<td></td>
<td>p53 Mutational Spectrum in Human Cancers: Clues to Cancer Etiology</td>
<td>Curtis Hams (1)</td>
</tr>
<tr>
<td>9:20</td>
<td></td>
<td>Wild-type p53 Protein Undergoes Nuclear Exclusion in Undifferentiated</td>
<td>Ute Moll (2)</td>
</tr>
<tr>
<td>9:35</td>
<td></td>
<td>Mutant p53 Protein Overexpression is Independently Associated with Poor</td>
<td>Michael Levesque (3)</td>
</tr>
<tr>
<td>9:50</td>
<td></td>
<td>Tumorigenesis Studies Using p53-Deficient Mice</td>
<td>Lawrence A. Donehower (4)</td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td>Germline p53 Mutations and Human Cancer</td>
<td>David Makin (5)</td>
</tr>
</tbody>
</table>

* 15 minute presentation selected from submitted abstracts
The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
1994
The seventh p53 workshop
Toronto, Canada
Muskoka

Just more good news:
*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

Monday, June 20

Session III: Structure/Function (1) - DNA Binding
Chair: John Jenkins

7:30 - 7:55  The Molecular Basis of p53 Function
John Jenkins

7:55 - 8:20  Biochemical Activities of p53
Hans Stahl (16)

8:20 - 8:45  Regulation of the Structure and Function of Wild-Type and Mutant Forms of p53
Carol Prives (17)

*8:45 - 9:00  p53 has Distinct Binding Sites for Single Stranded DNA Ends and Internal DNA Segments
Geroa Bukalov (18)

9:00 p.m. Coffee Break

9:30 - 9:55  Regulation of the DNA Binding Function and Stability of Human p53. Rescuing Wild Type Function from Mutant Proteins
David P. Lane (19)

9:55 - 10:20  Forms and Functions of p53
Jo Miller (20)

10:20 - 10:45  Co-crystall Structure of a p53-DNA Complex at 2.2 A
Yunje Cho (21)

*10:45 - 11:00  Structure/Function Analysis of the Conformational Flexibility and DNA Binding Activity of p53
Thanos D. Halazonetis (22)
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

Tuesday, June 21

Session IV: Structure/Function (2) - Gene Regulation
Chair: Moshe Oren

9:00 - 9:25 Target Genes of p53
Mashe Oren (23)

9:25 - 9:50 p53 and Sequence Specific Transactivation (SSAT)
Bert Vogelstein (24)

9:50 - 10:15 Functional Interactions Between p53 Tumor Suppressor Protein and Adenovirus Oncogene Products
Yugiao Shen (25)

10:15 - 10:30 Modulation of DNA Binding of p53 by the C-Terminus
Stephen J. Ullrich (26)

10:30 a.m. Coffee Break

11:00 - 11:25 Evidence for a Direct Involvement of p53 in Cellular DNA replication
Wolfgang Deppert (27)

11:25 - 11:50 Cellular Proteins that Bind to p53
Bin Li (28)

11:50 - 12:15 Characterization of the Mechanisms Underlying the HPV E6-Mediated Ubiquitination of p53
Jen Hulbregtse (29)

12:15 - 12:30 Gene Regulation by p53
Leonard Buckbinder (30)

12:30 - 12:45 Oligomerization and DNA Binding Properties of Wild Type Alternatively Spliced p53 Protein
Yuangang Liu (31)

12:45 p.m. Lunch
The seventh p53 workshop

Toronto, Canada Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

Wednesday, June 22

Session VI: Structure/Function (3) - Gene Regulation

Chair: Arnold J. Levine

8:45 - 9:10 Two Critical Amino Acids in the N-Terminal Domain of the p53 Protein are Required for Transcriptional Activation by Wild-Type and Some Mutant p53 Proteins as well as the Binding of MDM-2 and ADS E1B-55KD Oncogene products.

Arnold J. Levine (42)

9:10 - 9:35 Apoptosis, Chromosomal Damage and the p53 Tumour Suppressor Protein

Alan Bernstein (43)

9:35 - 10:00 p53 Growth and Transformation Suppression Functions

Karen Vousden (44)

*10:00 - 10:15 Study of the Mechanism of p53 Transcriptional Regulation

Xuan Liu (45)

*10:15 - 10:30 p53 Regulates the Human Epidermal Growth Factor Receptor Promoter Using its TBP-Binding Domain

Sumitra Deb (46)

10:30 a.m. Coffee Break

11:00 - 11:25 Factors Affecting p53 Expression and Function

Guillermina Lazaro (47)

*11:25 - 11:40 Cytoplasmic p53 binds Ribosomes and p53 mRNA

Robert Carroll (48)

*11:40 - 11:55 Conformational Change and Phosphorylation Modulate the Transcriptional Activity of Human p53 which may be Involved in Diverse Cellular Pathways

Wei Zhang (49)

12:00 p.m. Lunch and Departure
Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

The seventh p53 workshop
Toronto, Canada
Muskoka
The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
**1994**

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
<table>
<thead>
<tr>
<th>Page 1994</th>
</tr>
</thead>
</table>

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!

<table>
<thead>
<tr>
<th>p53 Antibodies: A New Marker in Lung Cancer?</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Lubin, L Bouchet, D Bengoulo, G Zalcman, J Trédanle, A Hirsch, T Soussi</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prognostic Significance of Autoantibodies Against p53 Protein in Human Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Lubin, JP Peyrat, J Bonneteille, L Vantemmons, J Fournier, T Soussi</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>UV-Induced p53 Mutations in Atypical Fibroxanthoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Maestro, AP Dei Tos, C Dogliotti, D Gasparotto, M Bolocchi, L Laurino, CDM Fletcher</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regulation of the Growth Suppressing Activity of p53</th>
</tr>
</thead>
<tbody>
<tr>
<td>H Tang, L Riesnick-Silverman, M Fonatov, Y Wang, C Prives, J Montedri</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reduction of Wild-Type p53 Enhances Sequence-Specific DNA Binding</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Rainwater, D Parks, P Tegtmeyer, K Mann</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigation of the Signalling Pathways that Modulate p53 Phosphorylation</th>
</tr>
</thead>
<tbody>
<tr>
<td>L Molenaar, DW Meek</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>p53-Mediated Tumor Cell Response to Therapeutic DNA Damage in Matched Pairs of Breast Cancer Specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>UM Moll, A Ostermeyer, J-C Aachomadegebe, M-C Mathieu, G Riu</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Murine p53 Bound to MDM-2 is Primarily Phosphorylated at Serine 389 and Serine 312</th>
</tr>
</thead>
<tbody>
<tr>
<td>J Momand</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expression of p53 after Stimulation of Quiescent Cells to Reenter the Cell Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>M Montenero, M König, D Sturm, E Schneider, K Appel, A Prowald, O-G Issinger, P Wagner</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence for a Second Cell Cycle Block of G2/M by p53</th>
</tr>
</thead>
<tbody>
<tr>
<td>N Stewart, G Hicks, D Litchfield, F Paraskevas, M Mowat</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Characterization of the Interaction of p53 with Matrix Attachment Region (MAR) DNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>B Müller, W Dippert</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>p53 Derived from Human Tumor Cell Lines Containing Distinct Point Mutations can be Activated to Bind p53 Target Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>D Niewolak, B Vojtšček and J Kovářík</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Different Tumor-derived p53 Mutants Display Distinct Conformational and Biological Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>K Ory, Y Legros, C Auguin, T Soussi</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Trans-Acivation of a Reporter Gene by Monomeric human p53</th>
</tr>
</thead>
<tbody>
<tr>
<td>KA Otto, RP Beckmann, IRN Rao</td>
</tr>
</tbody>
</table>
Just more good news:

*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
The seventh p53 workshop
Toronto, Canada
Muskoka

Just more good news:
*p53-DNA Crystals appeared!!
*K/O mice-grow tumors!!
*Germ line p53 mutations!!
1994

The seventh p53 workshop

Toronto, Canada
Muskoka

Just more good news:

*p53-DNA Crystals appeared!!  *K/O mice-grow tumors!!  *Germ line p53 mutations!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!

COMpanies & Other ORganisations HELPING TO Fund the 8th International P53 Workshop

Association for International Cancer Research
British Association for Cancer Research
Cancer Research Campaign
Pathological Society of Great Britain and Ireland

Bayer Corporation
Bristol-Meyers Squibb
Ciba-Geigy
Dako Ltd
Glaxo Wellcome
Invitrogen
Jouan
Meltek Scientific
NovoCastra
Onyx Pharmaceuticals
Pfizer Limited
Pharmacia Biotech
Schering Plough Research Institute
Serotec
Smith Kline Beecham
Scottish Enterprise Tayside
Zeneca
INTRODUCTION AND WELCOME

Welcome to Dundee! We hope that you enjoy your stay and that the meeting is both enjoyable and productive. We have been assisted by Margaret Barton and Sharon Milne as well as by all the members of our labs in making all the arrangements and we hope that everything goes as planned. We have included in the Abstract Book information about the meeting, about Dundee, about the social activities and other things that may be of interest and, perhaps, even of use. Where appropriate the authors of these contributions have been identified. We hope you find these additions valuable. However we clearly cannot take any responsibility for any inaccuracies and we hope that factual information is as up to date as possible.

We hope that you enjoy the Workshop and your visit to Scotland.

David Lane
Peter Hall
David Meek

MEETING ORGANISATION

All oral sessions of the Meeting are held in the Lecture Theatre of the West Park Centre and the posters are to be displayed in the West Park Villas. All meals are held in the Main Hall of the Residence except for the Conference Dinner which will be in Bonar Hall. Transport to this and to the other Social Events is organised and further details will be given during the meeting and posted by the Registration desks. Please wear your name badge throughout the Meeting and at all Social events.

Any problems or questions should be addressed to the staff at the Registration Desks, to any local organiser or to local staff members, who will be identifiable by their coloured badges.

LECTURES & POSTERS

Oral presentations are abstracts A1 to A48. Will speakers kindly note the timings and stick to them. This is essential given the nature of the programme. Some talks (those by invited speakers) are scheduled for 30 minutes in total i.e. 20 minutes presentation and 10 minutes discussion. Given the nature of the meeting and the audience lengthy introductions are obviously not needed. Short talks are derived from the submitted abstracts and have been chosen on the basis of quality, topicality and novelty. 15 minutes is allocated and this must include discussion so speakers should aim at a presentation of NO MORE THAN 8 minutes.

There are three poster sessions:-

- Session 1 (Saturday) Poster abstracts P1-P52
- Session 2 (Sunday) Poster abstracts P53-P101
- Session 3 (Monday) Poster abstracts P102-P149

Posters should be put up before 9 am on the day of the relevant poster session and should stay up for the whole day. Given the tight schedule we hope that you will make the full use of available time (before 9 am and at the end of the days session) as well as the formal Poster session from 11 am. Selected abstracts have been chosen for oral presentation as short talks - we expect these to be presented as posters as well.
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2
Relationship!!

SOCIAL EVENTS
We have arranged three main social events which will we hope be enjoyable as well as giving opportunities for further discussions. Transport to all is already arranged and details will be provided. Please ensure you do not miss any of the buses!

- RRS DISCOVERY & SCOTT OF THE ANTARCTIC
  Dundee's sea trading and ship building experience, particularly in the construction of whaling ships, led in 1899 to the National Antarctic Expedition Committee commissioning the building in Dundee of the RRS Discovery. This ship was launched in March 1901 having cost £51,000. It was based upon traditional whaling design with double hull and extra insulation against polar conditions. She undertook a number of surveys and voyages of discovery to the Antarctic commanded by Captain Robert F. Scott. Scott died along with his companions Wilson, Oates, Bowers and Petrie on the return journey, having reached the south pole one month after the Norwegian Amundsen in January 1912. The RRS Discovery returned to Dundee in 1986 is now a museum of Antarctic exploration.

- GLAMIS CASTLE
  Glamis Castle is a magnificent 15th century castle which incorporates earlier structures. The estate was given to Sir John Lyon by Robert the Second and Lyon's son became Lord Glamis in 1445. The 9th Earl became a Bowes Lyon on marrying a Yorkshire heiress called Bowes. The mother of the present Queen was born into this family and grew up at Glamis. The grounds were redesigned by the famous landscape gardener Capability Brown - an act that enraged Sir Walter Scott who preferred a more military style! Glamis is surrounded by history and myths - in the castle's Duncan's Hall, Macbeth (the Thane of Glamis) had supposedly entertained his intended victim!

- CONFERENCE DINNER & CEILIDH (pronounced "kay-lee")
  The conference dinner will be held in Bonar Hall next to the main University Campus on the Monday evening, preceded by a reception. The dinner will be followed by a ceilidh or Scottish dance - the best way to learn is to just join in!!

- "WHAT IS A CEILIDH?"
  "What precisely is a Ceilidh?" wondered the visiting international scientist as she placed the growing pile of conference notes onto the small table in her spartan yet adequate room.

  Later these notes would be collated, sorted and, after filtering, certain points could be applied to her exciting research back in her own lab where she knew the meaning of every word and nothing as important as a whole evening's events were so vaguely described or poorly understood. It was expecting the unexpected, the unknown that had made her mind wander as the last speaker of the afternoon concluded his talk. They all had been informed by the otherwise very informative programme that a Scottish ceilidh was an informal gathering of people where they danced and listened to the traditional dance music of Scotland.

  "But what does that really tell me?" she asked herself. So much was left unexplained. In more of a Hitchcock than Tarantino fashion it was exciting not knowing what to expect. It allowed her imagination to jump from picturing the RNA for p53 regally travelling (accompanied by yet unidentified waving chaperones) through super constructed nuclear pores, to this less researched phenomenon known only as a "Kay-lee". "Why were there no other words like it?" she puzzled. She had once overheard on a bridge in Kilkenny one old Irish man saying to another "Ah sure, didn't we sit up all night ceilidhing and there wasn't a soul in the house". From this she guessed there was a verb to "Kay-lee". She heard that years ago but never found out what it meant, for when she asked that old man what he had meant, he politely replied with a widening smile "The house was good and empty until they all came back from the hotel". She smiled at him and left, deciding not to pursue the word.
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!

But that was Ireland. She was now determined to sort this mysterious word out in her head. She knew that by going to the ceilidh and taking part in it, dancing and listening to the music she would experience the phenomenon. She could then translate, categorise and file the word for a time when a conversation would invite the use of such a word. She really thought she had it all sorted. She made sure she was wearing flat comfortable shoes and nothing too warm. They had been told by the programme that due to a lot of jumping, dancing, stepping and birling (the latter is where dancing partners try to centrifuge one another) one should wear sensible clothing akin to that of a logistically planned summer mountain trip. They all thought they could almost see the writer of the last piece of advice holding his hands to his mouth as he gave the innocents his mischievous advice. From some of the “kay-lee” experienced at the meeting she had this advice confirmed so she was gradually building up a mental picture of what to expect. As she boarded the bus with her new and rekindled friends she was becoming more and more sure that she had it all sorted.

On the bus she was told, by a proud Scottish man, resplendent, brave and century reversing in his dress, that the modern yet traditional band would explain how to do all the dances and that she should just follow everyone else, laugh, smile, skip and jump. Most dances were done in small groups of 3 to 6, though there were others. If she did all this she would come away with the real meaning of the word “ceilidh”. He said that once everybody was out on that wooden floor by the sea they were all in the same boat. He explained that the pleated tartan skirt reaching from his waist to his knees was known as a kilt. The other parts of his uniform were also very well made, especially the sporran, the pouch worn at the front of his kilt, though she was a bit shy to hold it and give it a good inspection. He also told her if the dancing was too new for her then the music alone would wake up the hi-fi cells and her tinnitus, instilled by every note, would dance higher than her feet could ever do. The music would take her running through Glens, over stony fast flowing waters, past purple heather, through forests, over long white sands, into darkened inns, past roaring aromatic log fires, past smiling laughing groups, beyond listening deer on snowy mountain tops and back to the hotel dance floor before the last note had faded and before synaptic vessels had started to reload.

She was full of excitement as the bus pulled up to the elegant chandeliered hotel. As co-electrifies glided in the nearby swelling tide and the sun headed across the Atlantic to wake up distant co-workers, they entered the grand surroundings of the hotel. All were relieved that they attained not too informally but had struck a balance with the etiquette of an elegant dinner and the work ahead in the “kay-lee” dancing.

After a wonderful, delightful, relaxed, beautiful, lit, tasty, wine drinking, laughing, clean linen, people watching, polished cutlery, sparkling glassed dinner and as the band started to quietly set up their instruments she was sure that she knew what lay ahead for the rest of the evening.

Then the music began . . . . well all I can tell you is this . . . . the feelings her dilated pupils expressed, two minutes later were those of sheer and total . . . . . . . . . . . . . . . . . . . . . . . . I hope I have explained to all of you what exactly a “kay-lee” is!

Declan Lunny

ABOUT DUNDEE

Dundee is located on the estuary of the River Tay on the eastern coast of Scotland roughly midway between Aberdeen and Edinburgh. The population of the city is approximately 174,000. The city has its own repertory theatre, cinema complex, and a number of fine restaurants and pubs. There are also regular concerts in the city including those given by the Royal Scottish National Orchestra and Scottish Chamber Orchestra. The cities of Perth and St. Andrews lie close by, each offering its own cultural aspects and Edinburgh is only an hour away by train or car.

The surrounding countryside offers sandy beaches, sea cliffs, rolling hills and superb mountain scenery with many activities including sailing, mountain climbing, hill walking, fishing and golf (with the internationally famous courses at St. Andrews, Carnoustie and Gleneagles as well as many others within easy reach).
Dundee provides access to other major parts of the country by train (only six hours to London) and daily flights to Manchester, Glasgow and Edinburgh airports are also within easy access (1 hour 30 min. and 1 hour by car respectively) offering international travel to all major destinations in Europe and North America.

One of the spectacular features of Dundee is the Tay bridge connecting Fife (to the south) with Dundee. However, this is the second rail bridge at this site! The first was commissioned by Parliament in 1870 and opened in 1878 having been built to a design by Sir Thomas Bouch. Unfortunately, not long after he was Knighted for this work, the bridge collapsed in a storm while a train was crossing on the night of 28th December 1879, killing 75 passengers and crew! The events of that night are remembered in a famous poem by the Dundonian writer William McGonagall, about whom John Keay has written:

"The combination of perversity, irrelevance, wayward rhymes and confused scansion has earned him the title of "the world's worst poet", a hard won and wholly deserved accolade which is entirely compatible with the affection with which McGonagall is held and the frequency with which he is quoted."

THE VERNACULAR or Dundonian for Beginners

In the following D = Dundonian and E = English

**Doctor**

D. Uill hay ti git a doctir
E. I need a doctor

D. Gon git iz a doctir
E. Would you fetch me a doctor please?

D. Zira doctir aboot?
E. Is there a doctor here?

Parts of the Body

<table>
<thead>
<tr>
<th>Dundonian</th>
<th>English</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ankul</td>
<td>Ankle</td>
</tr>
<tr>
<td>Ehrum</td>
<td>Arm</td>
</tr>
<tr>
<td>Bclud</td>
<td>Blood</td>
</tr>
<tr>
<td>Barrest</td>
<td>Breast</td>
</tr>
<tr>
<td>Chist</td>
<td>Chest</td>
</tr>
<tr>
<td>Lug</td>
<td>Ear</td>
</tr>
<tr>
<td>Elh</td>
<td>Eye</td>
</tr>
<tr>
<td>Fais</td>
<td>Face</td>
</tr>
<tr>
<td>Fingir</td>
<td>Finger</td>
</tr>
<tr>
<td>Fut</td>
<td>Foot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dundonian</th>
<th>English</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haid</td>
<td>Head</td>
</tr>
<tr>
<td>Heht</td>
<td>Heart</td>
</tr>
<tr>
<td>Ja</td>
<td>Jaw</td>
</tr>
<tr>
<td>Jynt</td>
<td>Joint</td>
</tr>
<tr>
<td>Lup</td>
<td>Lip</td>
</tr>
<tr>
<td>Mooth</td>
<td>Mouth</td>
</tr>
<tr>
<td>Mussul</td>
<td>Muscle</td>
</tr>
<tr>
<td>Noise</td>
<td>Noise</td>
</tr>
<tr>
<td>Shiddir</td>
<td>Shoulder</td>
</tr>
<tr>
<td>Theh</td>
<td>Thigh</td>
</tr>
</tbody>
</table>
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!

Little Bits and Bobs

D. Coors
E. Of course

D. Coors no
E. Of course not

D. Nay chans
E. Absolutely not

D. Awa yi go
E. You’re pulling my leg

D. Nah!
E. Really!

D. Gin yisrel
E. Good luck

D. Hard til bar
E. What bad luck

D. ‘saffy
E. How awful

D. ‘s brah
E. It is wonderful

D. Oh meh good
E. My goodness

D. Thank good
E. Thank goodness

Sharon Milne

RESTAURANT & PUB GUIDE

This is a brief (and personal) guide to local Dundee restaurants. There are many other excellent restaurants located in Perth and St. Andrews, please ask your helpful locals for details on these. Most places have daily specials which are excellent, ask the server or look for the in-house board. Most restaurants also have excellent vegetarian choices.

Reservations are recommended for the restaurants, especially at the weekend. The numbers beside the restaurant names refer to their position on the map. The conference centre is number 1 and the Department of Biochemistry, University of Dundee is number 2.

Food Anyone?

Pierre Vincent (3)
Corner of Castle & Dock Streets (phone 207777) French, cheap to moderately priced (3 course lunch £5, 3 course dinner £10) Open daily 0830 to 2200 and Sundays 1200 to 2100 h.

Het Theakatar (6)
Dundee Repertory Theatre, Tay Square off Perth Rd. (phone 206699) Varied menu, cheap to moderately priced (see sample menu) Open Mon.-Thurs. 1030 to 2000 and Fri.-Sat. 1030 to 2100 h.

Raffles (5)
18 Perth Rd. (phone 22344) Franco-Scottish menu, moderate to moderately priced. Open Tues.-Fri. 1200-1400, 1730-2130 h. Sat. 1130-2230 h.

Maderbaks (6)
304 Perth Rd. (phone 646281) Pizza, pasta, cajun menu, moderately priced Open daily from 1700 h.

Dandilier (7)
181-183 Perth Rd (phone 669218) Italian menu, moderately priced Open Tues.-Sat. 1730-2130 h.

Agabag Khub House (8)
113 Perth Rd. (phone 644227) Turkish Menu, moderately priced Open daily except Mon. 1730-2230 h.

Ishangi Tandoori (9)
1 Session St. (phone 20202) Indian Menu, moderately-expensively priced Open weekdays 1700-midnight, weekends 1700-0100 h.
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!

International Telephone Codes

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRALIA</td>
<td>00 61</td>
</tr>
<tr>
<td>AUSTRIA</td>
<td>00 43</td>
</tr>
<tr>
<td>CANADA</td>
<td>00 1</td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>00 42</td>
</tr>
<tr>
<td>FRANCE</td>
<td>00 33</td>
</tr>
<tr>
<td>GERMANY</td>
<td>00 49</td>
</tr>
<tr>
<td>INDIA</td>
<td>00 91</td>
</tr>
<tr>
<td>ISRAEL</td>
<td>00 972</td>
</tr>
<tr>
<td>ITALY</td>
<td>00 39</td>
</tr>
<tr>
<td>THE NETHERLANDS</td>
<td>00 31</td>
</tr>
<tr>
<td>NEW ZEALAND</td>
<td>00 64</td>
</tr>
<tr>
<td>RUSSIA</td>
<td>00 7</td>
</tr>
<tr>
<td>SINGAPORE</td>
<td>00 55</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>00 46</td>
</tr>
<tr>
<td>SWITZERLAND</td>
<td>00 41</td>
</tr>
<tr>
<td>TAIWAN</td>
<td>00 886</td>
</tr>
<tr>
<td>TUNISIA</td>
<td>00 216</td>
</tr>
<tr>
<td>U.S.A.</td>
<td>00 1</td>
</tr>
</tbody>
</table>

WORLD WIDE WEB AND p53
As many of you will know as an experiment we have placed information about the meeting on a World Wide Web page, accessed through

http://www.dundee.ac.uk/Biochemistry/
or through
http://www.dundee.ac.uk/Pathology/

We would be very interested to know how useful this was - please let Peter Hall know. We have decided that the Abstracts from the workshop will be available on this site after the meeting, so that others in the field can access the information presented. This is an experiment and again we are interested in your views as the value of this.

Please let Peter Hall know before the end of the meeting (leave a note at the desk) if you DO NOT wish your abstract to be included on this Web page. In addition we intend that the Names, E-mail addresses and FAX/phone numbers of participants will appear in a Directory attached to this Web page in due course. It seems to us that this will be a way of workers in the field more easily staying (and getting) in touch and will facilitate the work of the organiser(s) of the next workshop. Again let Peter Hall know if you DO NOT wish your address to be placed on the p53 Web Page. Finally, if there is additional information that you feel would be useful on the p53 Web page please let Peter Hall know.

Note:- We apologise for the error in the phone and FAX number on the WWW page - one too many whiskies (PAM!!)

WHISKY - a quick guide

Whisky is the Scottish drink. If spelt with an 'e' it is Irish! Whisky has been made and drunk in Scotland for thousands of years and the first tax was imposed in 1664! Malt whisky is made from a wattery extract of malted barley distilled in onion shaped pot stills. Blended whisky is a mixture of different whiskies including grain whisky and is designed to have a very consistent taste and price. They can be very good (try Old Grouse). However the best whiskies are Malt Whiskies. These are made in small distilleries and each has a very distinctive colour, taste and smell. There are more than 150 different malts that come from a range of different areas. Perhaps the best known area is from the distilleries along the banks of the river Spey. Another important area of whisky production are the islands including Orkney, Skye and Jura. Our favourites, should you wish to treat us at the bar, are Highland Park (Orkney), Macallan (Speyside) and Lagavulin (Islay).

Peter Hall, David Meek & David Lane
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Address/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varda Rotter</td>
<td>Weizmann Institute of Science, Rehovot, Israel</td>
<td>1996</td>
</tr>
<tr>
<td>Dr. A. Batmoul</td>
<td>The Eastern Institute for Cancer Research,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Garsenche Estate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Switchback Road                                GLASGOW G14 1BD</td>
<td></td>
</tr>
<tr>
<td>Dr. Alan Clarke</td>
<td>Department of Pathology, University of Edinburgh</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical School, CCR Laboratories, Teviot Place</td>
<td>EDINBURGH EH9 9AG</td>
</tr>
<tr>
<td>Dr. T. D. Hakenroth</td>
<td>Department of Molecular Oncology, The Wistar</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Institute, Philadelphia, PA 19104-4268 USA</td>
<td></td>
</tr>
<tr>
<td>Dr. R. Igo</td>
<td>EREC</td>
<td>CHEMIN DES BOVREMES 155 1965 Epalinges LAUSANNE SWITZERLAND</td>
</tr>
<tr>
<td>Professor A. J. Levine</td>
<td>Department of Molecular Biology, Princeton</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University, Lewis Thomas Laboratory, Princeton,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NJ 08544 USA</td>
<td></td>
</tr>
<tr>
<td>Dr. G. Morrow</td>
<td>Department of Microbiology, Jefferson Institute,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas Jefferson University, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19100 USA</td>
<td></td>
</tr>
<tr>
<td>Dr. W. E. Meren</td>
<td>Department of Microbiology and Immunology,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jefferson Institute, Thomas Jefferson University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Philadelphia, PA 19100 USA</td>
<td></td>
</tr>
<tr>
<td>Dr. S. Benichou</td>
<td>Ontario Cancer Institute, 560 Sherbourne Street,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6th Floor, Toronto, Ontario  M4X 1K9 CANADA</td>
<td></td>
</tr>
<tr>
<td>Dr. W. Donohue</td>
<td>Institute of Molecular Biology, Baylor College</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of Medicine, One Baylor Plaza, Houston, TX 77030</td>
<td></td>
</tr>
<tr>
<td>Dr. L. Harper</td>
<td>Department of Pathology, University of Dundee,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ninewells Hospital, Dundee, DD1 5ES SCOTLAND</td>
<td></td>
</tr>
<tr>
<td>Dr. John Jenkins</td>
<td>Maria Curie Institute, The Chart, Gos/</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surrey RM8 0TL ENGLAND</td>
<td></td>
</tr>
<tr>
<td>Dr. S. W. Levis</td>
<td>Cold Spring Harbor Laboratory, Cold Spring</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harbor Box 100 Long Island, New York, NY 11724-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2203 USA</td>
<td></td>
</tr>
<tr>
<td>Dr. E. May</td>
<td>Laboatoire de Cancrologie, Montlucon, 42100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CNRS/CNRA, 95665 Fontaine les Roses, FRANCE</td>
<td></td>
</tr>
<tr>
<td>Dr. Minnie Nacht</td>
<td>40 Avon Street, Bldg. 617-219, M.I.T. Cambridge,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MA 02139 USA</td>
<td></td>
</tr>
</tbody>
</table>
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Department/Division</th>
<th>Address</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. A. Mocacico</td>
<td>Dept. of Biochemistry</td>
<td>University of Oxford</td>
<td>South Parks Road, Oxford</td>
<td>U.K.</td>
</tr>
<tr>
<td>Dr. T. Myhr</td>
<td>Dept. of Surgery</td>
<td>Addenbrooke's Hospital</td>
<td>CAMBRIDGE CB2 2QQ</td>
<td>U.K.</td>
</tr>
<tr>
<td>Dr. J. Mortam</td>
<td>City of Hope National Med Center</td>
<td>Dep. of Cell &amp; Tumor Biology</td>
<td>1500 East Duarte Rd, Duarte</td>
<td>U.S.A.</td>
</tr>
<tr>
<td>Dr. O. Mor</td>
<td>I.C.R.F.</td>
<td>44 Lincoln's Inn Fields</td>
<td>LONDON</td>
<td>U.K.</td>
</tr>
<tr>
<td>Dr. B. F. Mueller</td>
<td>Bayer Corporation Pharmacy</td>
<td>Cancer Res. 400 Morgan Lane West</td>
<td>CT 06905</td>
<td>U.S.A.</td>
</tr>
<tr>
<td>Dr. M. Mukai</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. D. M. Nanda</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. K. Nakahara</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. M. M. Nielsen</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. V. Olavskaya</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. D. R. Onishio</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. A. Ortoni</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. V. Otsuka</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. J. Sato</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
<tr>
<td>Dr. K. Sato</td>
<td>Dep. of Pathology</td>
<td>Inst. for Experimental Carcinogenesis</td>
<td>Freiburgerstr. 2, 74000</td>
<td>GERMANY</td>
</tr>
</tbody>
</table>

1996

**The eight p53 workshop**

Dundee Scotland

**P53-based therapy?**

**More about the p53-mdm2 Relationship!!**
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
P53-based therapy?

More about the p53-mdm2 Relationship!!

**The eight p53 workshop**

Dundee
Scotland

1996
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2
Relationship!!
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
The eight p53 workshop
Dundee
Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!

**OUTLINE PROGRAMME**

<table>
<thead>
<tr>
<th>Friday 5th July</th>
</tr>
</thead>
<tbody>
<tr>
<td>From 3.00 Registration</td>
</tr>
<tr>
<td>6.30 Dinner</td>
</tr>
<tr>
<td><strong>Session 1</strong></td>
</tr>
<tr>
<td>7.45 pm Introductory remarks by DP Lane</td>
</tr>
<tr>
<td>8.00 <strong>AJ Levine (A1)</strong> The Cancer Research Campaign Lecture Identification of a new p53 functional domain which is necessary for transcription independent growth suppression</td>
</tr>
<tr>
<td>8.30 <strong>CC Harris (A2)</strong> p53 Tumour Suppressor Gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer therapy</td>
</tr>
<tr>
<td>9.00 <strong>AJ Wyllie (A3)</strong> DNA stability and apoptosis in p53 deficient cells</td>
</tr>
<tr>
<td>9.30 <strong>F McCormick (A4)</strong> The Onyx Lecture An adenovirus mutant that replicates in p53 deficient human tumour cells</td>
</tr>
<tr>
<td>10.00 Further discussions in the bar</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Saturday 6th July</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30 Breakfast &amp; poster viewing</td>
</tr>
<tr>
<td><strong>Session 2</strong></td>
</tr>
<tr>
<td>9.00 <strong>S Jackson (A5)</strong> DNA dependent protein kinase: a paradigm for DNA damage sensing systems</td>
</tr>
<tr>
<td>9.30 <strong>G Wahl (A6)</strong> p53 mediated arrest triggered in the absence and presence of DNA damage in normal human fibroblasts</td>
</tr>
<tr>
<td>10.00 <strong>PA Hall (A7)</strong> On the ontology of the p53 response and its upstream and downstream coupling</td>
</tr>
<tr>
<td>10.30 <strong>E May (A8)</strong> Development of a transgenic mouse model which permits an in vivo approach to study wild type p53 properties</td>
</tr>
<tr>
<td>11.00 Coffee &amp; Poster session 1</td>
</tr>
<tr>
<td>12.30 Lunch and further poster viewing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.00 <strong>W Deppert (A9)</strong> The Association for International Cancer Research Lecture Characterisation of the 3' → 5' exonuclease activity of the p53 protein</td>
</tr>
<tr>
<td>2.30 <strong>T Tsuts (A10)</strong> A p53 mutant provides a gain-of-function phenotype affecting cell cycle checkpoint control</td>
</tr>
</tbody>
</table>
The eight p53 workshop
Dundee Scotland

P53-based therapy?
More about the p53-mdm2 Relationship!!
The eight p53 workshop  
Dundee  
Scotland

**P53-based therapy?**

**More about the p53-mdm2 Relationship!!**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td><strong>Short talks</strong></td>
</tr>
<tr>
<td></td>
<td>A Godkov (A23/P96) Dissection of p53 functions by genetic suppressor elements: cellular effects of separate p53 domains</td>
</tr>
<tr>
<td></td>
<td>C Desaintes (A24/P97) Expression of the papillomavirus E2 protein in HeLa cell increases p53 transcriptional activity and leads to apoptosis</td>
</tr>
<tr>
<td></td>
<td>N Horikoshi (A25/P98) Adenovirus E4 ORF6 protein blocks transcriptional activity by the p53 tumour suppressor protein</td>
</tr>
<tr>
<td>3.15</td>
<td><strong>Tea</strong></td>
</tr>
<tr>
<td>4.15</td>
<td><strong>Short talks</strong></td>
</tr>
<tr>
<td></td>
<td>P Sabatini (A26/P99) Regulation of p53 dependent apoptosis by adenoviral oncogenes</td>
</tr>
<tr>
<td></td>
<td>M Rolfe (A27/P100) In vitro studies of HPV18-E6 stimulated p53 ubiquitination: E6/E6AP binding is separable from ubiquitination and subsequent degradation</td>
</tr>
<tr>
<td></td>
<td>D Pim (A28/P101) An alternatively spliced form of HPV-18 E6 (E6*) modulates the association between full length E6 and p53.</td>
</tr>
<tr>
<td>5.00</td>
<td>V Rotter (A29) Mutant p53 protein interrupts cell differentiation and apoptosis</td>
</tr>
<tr>
<td>5.30</td>
<td>M Kastan (A30) The role of p53 in modulation of cell cycle, cell differentiation and cell death following DNA damage</td>
</tr>
<tr>
<td>6.00</td>
<td>End of session</td>
</tr>
<tr>
<td>6.15</td>
<td><strong>Dinner</strong></td>
</tr>
<tr>
<td>7.15</td>
<td>Visit to Glamis Castle</td>
</tr>
</tbody>
</table>

**Monday 8th July**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30</td>
<td><strong>Breakfast &amp; poster viewing</strong></td>
</tr>
</tbody>
</table>
| 9.00  | Session 6 Regulation I  
|       | Chair - K Vousden (Frederick)                   |
|       | S Benchimol (A31) Translational regulation of human p53 gene expression |
| 9.30  | D Meeke (A32) Phosphorylation of p53 by stress and DNA damage activated protein kinases |
| 10.00 | T Huppa (A33) The major protein phosphatase from murine liver targeting the C terminal regulatory domain of p53 is a PP2A homologue specific for the protein kinase C phosphorylation site |
| 10.30 | C Prives (A34) Regulation of p53 tumour suppressor functions |
| 11.00 | **Coffee & Poster session 3**                   |
| 12.30 | Lunch and further poster viewing               |
1996

The eight p53 workshop
Dundee
Scotland

P53-based therapy?

More about the p53-mdm2 Relationship!!
The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost everyone agrees with everyone!

Are we ready for the clinical trials?

9th p53 Workshop
Elunda Beach
Crete
Greece

May 9–13, 1998
1998

The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?

9th p53 Workshop Website
http://athens.wistar.upenn.edu/p53

The WWW Page of the 9th International p53 Workshop
May 9–13, 1998
Crete, Greece

9th International p53 Workshop Registration and Information
Directory of Scientists in the p53 Field
Profiles of p53 Laboratories
Bulletin Board
Job Fair
Scientific Contributions
p53 in the News
Reagents for p53 Research
Information About this Site

Major Sponsorship Provided by:

Genentech
Merck Sharp & Dohme
Pharmacia Biotech
Rhone–Poulenc Rorer
The Wistar Institute
The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost everyone agrees with everyone!

Are we ready for the clinical trials?
1998

The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?
Welcome Address

On behalf of the organizing committee, I want to welcome you to Elounda, Greece and to the 9th p53 Workshop. Thank you for coming.

It has been 2 years since the Workshop in Dundee, Scotland. During this time there have been several major developments in our field. Some of these developments have been published and others will be presented here for the first time. Our gathering here will provide us with the opportunity to discuss the new findings and to set our compass for the direction of research each of us will pursue.

The last two years have also been years of major advances in fields that are highly relevant to p53, such as transcription, apoptosis and DNA damage signaling. The organizers felt that it would be useful to discuss p53 in the context of these advances and invited scientists who traditionally have not attended p53 Workshops. We hope that the presence of these scientists will benefit all of us and we thank them for their participation.

Science alone does not make a Workshop successful. Our ability to be here today is entirely dependent on the generosity of our sponsors. Twenty-two pharmaceutical and biotechnology companies donated generously to keep the registration fee of each participant to the lowest possible level. In addition, the National Institutes of Health of the USA supported 17 predoctoral and postdoctoral fellowships; the European Molecular Biology Organization sponsored the participation of Dr. David Lane; and the Pathological Society of Great Britain and Ireland sponsored the participation of Dr. Carol Prives. On behalf of all the organizers I want to express to our sponsors our gratitude for the valuable support we have received.

The financial and organizational administration of the p53 Workshop was through the Wistar Institute in Philadelphia, USA. Wistar provided a dedicated server for the Workshop, which all of you have visited to register, submit your abstracts and find information about the Workshop. Wistar also managed the financial side of the Workshop and monitored the funds received and funds spent. I am especially grateful to Dr. Giovanni Rovera, the Director of Wistar, and the staff of the finance and computer departments for this support. I also wish to thank the graduate students and postdoctoral fellows of the Institute of Molecular Biology and Biotechnology in Crete and of the Medical Schools of the Universities of Crete and Athens, who are helping us at the registration desk and with the audiovisual equipment.

I am especially pleased that the 9th p53 Workshop is being held at the Elounda Beach Conference Center. The spacious conference rooms, the beauty of the natural surroundings and the service are unparalleled. Our thanks go to the management and staff who responded to all our needs.

This Workshop would not have been possible without the support of all the co-organizers, who helped with the scientific organization and the fund raising. To all of them, I express my sincere gratitude. Finally, let me thank my students and my wife, who allowed me to invest the enormous amount of time that was required to organize this Workshop.

Sincerely,

Thanos Halazonetis
The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?
1998

The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?

Sponsored Lectures

David Lane, U. Dundee,
spared by

EMBO

Carol Prives, Columbia U.,
spared by the

Pathological Society of Great Britain and Ireland
1998

The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?

Recipients of NIH Fellowship Awards

Dr. Fred Bunz, Johns Hopkins University
Mr. Nabil Chehab, University of Pennsylvania
Dr. Lynda Chin, Albert Einstein College of Medicine
Dr. Gargi Dasgupta, City of Hope National Medical Center
Dr. Nicholas Denko, Stanford University
Dr. Steven DiBiase, Thomas Jefferson University
Mr. Sean Downing, University of New South Wales
Ms. Deborah Friedman, Princeton University
Dr. Irina Grigorian, University of Illinois at Chicago
Dr. Paul Hwang, Johns Hopkins University
Ms. Shireen Khan, The Salk Institute
Dr. Constantinos Koumenis, Stanford University
Ms. Denise Piscopo, Harvard University
Ms. Leslie Saucedo, University of Wisconsin
Mr. Daniel Scolnick, University of Pennsylvania
Dr. Sheau-Yann Shieh, Columbia University
Mr. Stuart Tyner, Baylor College of Medicine
The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?

Program of Events

Saturday, May 9

6:00–8:00 Dinner

Oral Presentations: Keynote Speakers

8:00 – 8:15 Thanos Halazonetis (Wistar Institute, USA) – Welcome
8:20 – 9:10 Arnold Levine (Princeton U., USA)
9:10 – 10:00 David Lane (U. Dundee, UK)
10:15 – 11:15 Welcome Reception
The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost everyone agrees with everyone!

Are we ready for the clinical trials?
1998

The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?

Monday, May 11

Oral Presentations: Regulation of p53 Function
Chairperson: Guillermina Lozano (MD Anderson Cancer Center, USA)

8:30 – 8:50  Karen Vousden (NCI, USA)
8:55 – 9:15  Lynda Chin (Albert Einstein College of Medicine, USA)
9:20 – 9:40  Steven Grossman (Dana Farber Cancer Inst., USA)
9:45 – 10:05 Geoffrey Wahl (Salk Institute, USA)
10:10 – 10:30 Thea Tlsty (UCSF, USA)
10:35 – 11:00  Question and Discussion Session
11:00 – 11:30 Coffee Break

Oral Presentations: p53 Structure–Function
Chairperson: Stephen Fesik (Abbott Laboratories, USA)

11:30 – 11:50 Rodney Harrington (U. Reno, USA)
11:55 – 12:10 Cheryl Arrowsmith (U. Toronto, Canada)
12:15 – 12:30 Elena Stavridi (Wistar Institute, USA)
12:35 – 12:50  Question and Discussion Session
12:50 – 2:15 Lunch
2:15 – 6:00  Visit to Knossos
6:00 – 8:00 Dinner

Oral Presentations: DNA Damage
Chairperson: Jan Hoeijmakers (Erasmus U., Netherlands)

8:00 – 8:25  Jan Hoeijmakers (Erasmus U., Netherlands)
8:30 – 8:55  Michael Karin (UCSD, USA)
9:00 – 9:25  Yosef Shiloh (Tel Aviv U., Israel)
9:30 – 9:50  Merl Hoekstra (ICOS, USA)
9:55 – 10:15 George Iliakis (Thomas Jefferson U., USA)
10:20 – 10:50  Question and Discussion Session
The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost everyone agrees with everyone!

Are we ready for the clinical trials?

Tuesday, May 12

Oral Presentations: DNA Damage and p53
Chairperson: Michael Karin (UCSD, USA)

8:25 – 8:50 Carol Prives (Columbia U., USA)
8:55 – 9:15 Michael Kastan (Johns Hopkins U., USA)
9:20 – 9:40 David Mekel (U. Dundee, UK)
9:45 – 10:05 Thanos Halazonetis (Wistar Institute, USA)
10:10 – 10:30 Kum Kum Khanna (Queensland I. Medical Research. Australia)
10:35 – 11:00 Question and Discussion Session
11:00 – 11:30 Coffee Break

Oral Presentations: More DNA Damage and p53 Regulation
Chairperson: Yosef Shiloh (Tel Aviv U., Israel)

11:30 – 11:50 Wolfgang Deppert (U. Hamburg, Germany)
11:55 – 12:15 Curtis Harris (NCI, USA)
12:20 – 12:30 Scott Lowy (Cold Spring Harbor Laboratory, USA)
12:35 – 1:00 Question and Discussion Session
1:00 – 2:30 Lunch
2:30 – 4:45 Poster Session 2

Oral Presentations: Therapy
Chairperson: Varda Rotter (Weizmann Institute, Israel)

5:00 – 5:20 Stephen Chang (Canji, USA)
5:25 – 5:40 Cecile Bougeret (Rhone Poulenc Rorer, France)
5:45 – 6:05 David Kim (Onyx Pharmaceuticals, USA)
6:10 – 6:25 Klas Wiman (Karolinska Institute, Sweden)
6:30 – 6:50 Kenneth Koblan (Merck Research Laboratories, USA)
6:55 – 7:20 Question and Discussion Session
8:00 – 12:00 Gala Dinner (Cretan Night)
1998

The ninth p53 workshop
Elunda Beach
Crete
Greece

A wonderful meeting almost every one agrees with everyone!

Are we ready for the clinical trials?

Wednesday, May 13

Oral Presentations: p53 Family Members
Chairperson: Daniel Caput (Sanofi Research, France)

8:30 – 8:50 Daniel Caput (Sanofi Research, France)
8:55 – 9:15 William Kaelin (Dana Farber Cancer I., USA)
9:20 – 9:30 Casimir Bamberger (U. Hamburg, Germany)
9:30 – 9:50 Question and Discussion Session

9:50 – 10:15 Coffee Break

Oral Presentations: Cell Cycle and Tumor Suppression
Chairperson: Thea Tlsty (UCSF, USA)

10:15 – 10:35 Guillermima Lozano (MD Anderson Cancer Center, USA)
10:40 – 11:00 Lawrence Donehower (Baylor College of Medicine, USA)
11:05 – 11:25 Andrei Gudkov (U. Illinois at Chicago, USA)
11:30 – 11:45 Laurent Debussche (Rhone Poulenc Rorer, France)
11:50 – 12:05 Demetrios Spandidos (U. Crete, Greece)
12:10 – 12:35 Question and Discussion Session
12:40 – 12:45 Thank Participants

12:45 – 2:00 Lunch
The tenth p53 workshop
Monterey
USA
### Organizers

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Address</th>
<th>Phone</th>
<th>Fax</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thea Tlsty, Ph.D.</td>
<td>University of California, San Francisco</td>
<td>HSW 451, Box 0506 San Francisco, CA 94143-0506</td>
<td>415-502-6776</td>
<td>415-502-6163</td>
<td><a href="mailto:tlstv@itsa.ucsf.edu">tlstv@itsa.ucsf.edu</a></td>
</tr>
<tr>
<td>Thanos Halazonetis, Ph.D.</td>
<td>Wistar Institute</td>
<td>3601 Spruce Street Philadelphia, PA 19104-4268</td>
<td>215-898-3789</td>
<td>215-898-3929</td>
<td><a href="mailto:halazonetis@wistar.upenn.edu">halazonetis@wistar.upenn.edu</a></td>
</tr>
<tr>
<td>David Lane, Ph.D.</td>
<td>University of Dundee, Dept. of Biochem.</td>
<td>Dow Street, MSI/WTB Complex Dundee DD1 5EH United Kingdom</td>
<td>138234921</td>
<td>1382322558</td>
<td><a href="mailto:D.P.Lane@dundee.ac.uk">D.P.Lane@dundee.ac.uk</a></td>
</tr>
<tr>
<td>Jo Miliner, Ph.D.</td>
<td>University of York, Dept. of Biology</td>
<td>YCR p53 Research Group, York YO10 5DD United Kingdom</td>
<td>44-1904-432891</td>
<td>44-1904-432808</td>
<td><a href="mailto:ajmil@york.ac.uk">ajmil@york.ac.uk</a></td>
</tr>
<tr>
<td>Carol Prives, Ph.D.</td>
<td>Columbia University, Dept. of Bio. Science</td>
<td>816 Fairchild Building New York, NY 10027</td>
<td>212-854-2557</td>
<td>212-865-8246</td>
<td><a href="mailto:prives@cubsp.columbia.edu">prives@cubsp.columbia.edu</a></td>
</tr>
<tr>
<td>Varda Rotter, Ph.D.</td>
<td>Weizmann Institute of Science</td>
<td>Dept. of Molecular Cell Biology, Rehovot 76100 Israel</td>
<td>972-8-946-4501</td>
<td>972-8-946-5265</td>
<td><a href="mailto:rotter@weizmann.ac.il">rotter@weizmann.ac.il</a></td>
</tr>
<tr>
<td>Geoffrey Wahl, Ph.D.</td>
<td>Salk Institute, Gene Expression Lab</td>
<td>10010 N. Torrey Pines Road La Jolla, CA 92037-1099</td>
<td>858-453-4100, Ext. 1255</td>
<td>858-457-2762</td>
<td><a href="mailto:wahl@salk.edu">wahl@salk.edu</a></td>
</tr>
<tr>
<td>Frank McCormick, Ph.D., FRS (Co-chair)</td>
<td>University of California, San Francisco</td>
<td>2340 Sutter Street, Box 0128 San Francisco, CA 94143-0128</td>
<td>415-502-1710</td>
<td>415-502-1712</td>
<td><a href="mailto:mccormick@cc.ucsf.edu">mccormick@cc.ucsf.edu</a></td>
</tr>
<tr>
<td>Curtis Harris, M.D.</td>
<td>Laboratory of Human Carcinogenesis, NCI/NIH</td>
<td>37 Convent Drive, Bldg. 27, Room 2C075 Bethesda, MD 20892</td>
<td>301-496-2048</td>
<td>301-496-0457</td>
<td><a href="mailto:Curtis_Harris@nih.gov">Curtis_Harris@nih.gov</a></td>
</tr>
<tr>
<td>Arnold Levine, Ph.D.</td>
<td>Rockefeller University</td>
<td>1230 York Avenue New York, NY 10021-6399</td>
<td>212-327-8080</td>
<td>212-327-8900</td>
<td><a href="mailto:alevine@rockvax.rochester.edu">alevine@rockvax.rochester.edu</a></td>
</tr>
<tr>
<td>Moshe Oren, Ph.D.</td>
<td>Department of Molecular Cell Biology</td>
<td>The Weizmann Institute of Science</td>
<td>972-8-934-2358</td>
<td>972-8-946-5223</td>
<td><a href="mailto:Oren@weizmann.ac.il">Oren@weizmann.ac.il</a></td>
</tr>
<tr>
<td>Karen Vousden, Ph.D.</td>
<td>NCI FCRDC</td>
<td>West 7th Street Frederick, MD 21702-1201</td>
<td>301-846-1726</td>
<td>301-846-1666</td>
<td><a href="mailto:vousden@ncifcrf.gov">vousden@ncifcrf.gov</a></td>
</tr>
</tbody>
</table>

**The tenth p53 workshop**

Monteray USA
The tenth p53 workshop
Monteray
USA
## Recipients of NIH Fellowship Awards

<table>
<thead>
<tr>
<th>Recipient</th>
<th>Mentor</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ayed, Ayeda</td>
<td>Dr. Cheryl Arrawsmith</td>
<td>Ontario Cancer Institute</td>
</tr>
<tr>
<td>Bensaad, Karim</td>
<td>Dr. Thierry Soussini</td>
<td>Institute Curie</td>
</tr>
<tr>
<td>Berger, Michael</td>
<td>Dr. Ygal Haupt</td>
<td>The Hebrew University</td>
</tr>
<tr>
<td>Erez-Alon, Neta</td>
<td>Dr. Varda Rotter</td>
<td>Weizmann Institute of Science</td>
</tr>
<tr>
<td>Latonen, Leena</td>
<td>Dr. Mariikki Laiho</td>
<td>Haartman Institute, Univ. of Helsinki</td>
</tr>
<tr>
<td>Maya, Ruth &amp; Blander, Gil</td>
<td>Dr. Moshe Oren</td>
<td>Weizmann Institute of Science</td>
</tr>
<tr>
<td>Meplan, Catherine</td>
<td>Dr. David Moek</td>
<td>University of Dundee</td>
</tr>
<tr>
<td>Nozell, Susan</td>
<td>Dr. Xinbin Chen</td>
<td>Medical College of Georgia</td>
</tr>
<tr>
<td>Palecek, Jan</td>
<td>Dr. Emil Palecek</td>
<td>Academy of Sciences Czech Republic</td>
</tr>
<tr>
<td>Thornborrow, Edward</td>
<td>Dr. James Manfredi</td>
<td>Mount Sinai School of Medicine</td>
</tr>
</tbody>
</table>
2000

The tenth p53 workshop
Monteray
USA

Speakers

**Appella, Ettore**, Dr.
National Cancer Institute
Bldg., 37, R1B03
Bethesda MD 20892
Tel: 301 402 4177
Fax: 301 496 7220
E-mail: appella@pop.ncl.nih.gov

**Arrowsmith, Cheryl**, Pr.
University Health Network: Ontario Cancer
Princess Margaret Hospital
610 University Avenue, 7-718
Toronto M5G 2M9
Canada
Tel: 416 946 2017
Fax: 416 946 6529
E-mail: carrow@oci.utoronto.ca

**Benchimol, Sam**, Pr.
Ontario Cancer Institute
610 University Avenue
Toronto ONT M5G 2M9
Canada
Tel: 416 946 2955 & 2956 AA
Fax: 416 946 2065
E-mail: benchimo@oci.utoronto.ca

**Borresen-Dale, Anne-Lise**, Pr.
The Norwegian Radium Hospital
Ullernchausseen 70
Oslo 0310
Norway
Tel: 47 229 34419
Fax: 47 22934440
E-mail: alb@radium.uio.no

**Brodsky, Michael**, Dr.
UC Berkeley
Room 539, LSA Bldg., Dept. of MCB
Berkeley CA 94720
Tel: 510 643 9944
Fax: 510 643 9947
E-mail: brodsky@uclink4.berkeley.edu

**Cordon-Cardo, Carlos**, Dr.
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York NY 10021
Tel: 212 639 7746
Fax: 212 749 3186
E-mail: cordon-c@mskcc.org

**Deppert, Wolfgang**, Pr.
Heinrich-Pette Institute
Martinistrasse 52
Hamburg D-20251
Germany
Tel: 49 40 48051 261
Fax: 49 40 48051 117
E-mail: deppert@hpi.uni-hamburg.de

**Donchower, Larry**, Dr.
Baylor College of Medicine
One Baylor Plaza
Houston TX 77030
Tel: 713 798 3594
Fax: 713 798 3490
E-mail: larryd@bem.tmc.edu
The tenth p53 workshop
Monterey USA
2000

The tenth p53 workshop
Monteray
USA
2000

The tenth p53 workshop
Monteray
USA

Wahl, Geoff, Dr.
The Salk Institute
10010 N. Torrey Pines Road
La Jolla  CA  92037
Tel:  858 453 4100 x1587
Fax:  858 457 2762
E-mail: wahl@salk.edu
# Program of Events

**Wednesday, April 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 9:00</td>
<td>Breakfast at your hotel</td>
</tr>
<tr>
<td>7:30 - 9:00</td>
<td>Sign-in/Registration - Monterey Conference Center</td>
</tr>
<tr>
<td>9:00 - 9:15</td>
<td>Introductory Remarks: Thea Tlsty</td>
</tr>
</tbody>
</table>

**Session 1: In vivo Studies**

- **Chair:** Jenny Varley

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 - 9:45</td>
<td>Jenny Varley</td>
<td>Genotype and Phenotype in Carriers of Germline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TP53 Mutations</td>
</tr>
<tr>
<td>9:45 - 10:15</td>
<td>Carlos Cordon-Cardo</td>
<td>p53 Alterations are Associated With Clinical Outcome</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Anne-Lise Borreson Dale</td>
<td>Influence of TP53 Gene Alterations on the Response to Treatment With Doxorubicin in</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Locally Advanced Breast Cancer, and Relation to the Molecular Expression Portraits Using eDNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Microarrays</td>
</tr>
</tbody>
</table>

**10:30 - 11:00** Coffee Break

**Session 2: p53 Structure**

- **Chair:** Thierry Soussi

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:30</td>
<td>Thierry Soussi</td>
<td>Structure-Function Relationships of the p53 Protein</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Wolfgang Deppert</td>
<td>Interaction of p53 with DNA Polymerase α</td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td>Cheryl Arrowmith</td>
<td>Probing for a Structural Basis for the Autoregulation of p53 by the C-Terminal Domain</td>
</tr>
<tr>
<td>12:15 - 2:00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

**Session 3: Family Members**

- **Chair:** Frank McKeon

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 - 2:30</td>
<td>Frank McKeon</td>
<td>p53 and p73: from Epithelial Stem Cells to Neurogenesis</td>
</tr>
<tr>
<td>2:30 - 3:00</td>
<td>William Kaelin</td>
<td>Functional Analysis of the p53 Homolog p73</td>
</tr>
<tr>
<td>3:00 - 3:30</td>
<td>David Sidransky</td>
<td>Oncogenic Function of p40/p63</td>
</tr>
<tr>
<td>3:30 - 3:45</td>
<td>Michael Brodsky</td>
<td>DNA Damage Responses in Drosophila</td>
</tr>
<tr>
<td>3:45 - 4:00</td>
<td>Casey Kopecky</td>
<td>Drosophila p53 is a Structural and Functional Homologue of the p53 Tumor Suppressor</td>
</tr>
</tbody>
</table>

**4:00 - 6:00** Poster Session 1 (Last name of presenter: A-K)

**7:00 - 9:00** Dinner at the Casa Munras Garden Hotel, 700 Munras Avenue
Thursday, April 6

7:30 - 9:00 Breakfast at your hotel

Session 4: In vivo Studies
Chair: Guillermina Lozano

9:00 - 9:30 Guillermina Lozano
A New Mouse Model Inheriting a p53 Missense Mutation

9:30 - 10:00 Larry Donehower
A Germline p53 Mutation That Confers Tumor Resistance and Altered Longevity in Mice

10:00 - 10:30 Geoffrey Wahl
A Transactivation-Deficient Mouse Model Provides Insights into p53 Regulation and Function in Vivo

10:30 - 11:00 Coffee Break

Session 5: p53 Phosphorylation
Chair: Carol Prives

11:00 - 11:30 Carol Prives
The Role of Stress Kinases in the Regulation of p53 Stability and Activity

11:30 - 12:00 Thanos Halazonetis
ATM-Dependent Regulation of p53 Phosphorylation of Ser46 Regulates Apoptosis-Inducing Ability of p53

12:00 - 12:30 Yoichi Taya
Regulation of p53 by Human CDC14 Phosphatase

12:15 - 12:30 Mats Ljungman
p53 and DNA Repair?

12:30 - 2:00 Lunch

Session 6: DNA Damage: Sensing & Repair
Chair: Varda Rotter

2:00 - 2:30 Varda Rotter
Induction of p53-Dependent DNA Repair or Onset of p53-Dependent Apoptosis: a Question of Cell Cycle Phase

2:30 - 3:00 Jo Milner
p53-Mediated Apoptotic Pathways

3:00 - 3:30 Curtis Harris
p53 and ATM in Cytotoxic Stress Responses

3:30 - 4:00 Michael Kastan
p53 and DNA Repair

4:00 - 6:00 Free time

6:45 p.m.
Discovery Bus pick-up #1 from your hotel to the Monterey Bay Aquarium

7:15 p.m.
Discovery Bus pick-up #2 from your hotel to the Monterey Bay Aquarium

7:00 - 11:00 Dinner at the Monterey Bay Aquarium (Strolling Dinner & Viewing)

9:30 p.m.
Discovery Bus pick-up #1 from the Monterey Bay Aquarium to your hotel

10:00 p.m.
Discovery Bus pick-up #2 from the Monterey Bay Aquarium to your hotel

10:30 p.m.
Discovery Bus pick-up #3 from the Monterey Bay Aquarium to your hotel

11:00 p.m.
Discovery Bus pick-up #4 from the Monterey Bay Aquarium to your hotel
The tenth p53 workshop
Monteray
USA
The tenth p53 workshop
Monteray
USA

Saturday, April 8
7:30 - 9:00  Breakfast at your hotel

Session 10:  In Vivo Studies
9:00 - 9:30  Terry Van Dyke  p53 Tumor Suppression in the Mouse
9:30 - 10:00 Joseph Jerry  Compromised Function of p53 in Mammary Epithelium of Nulliparous Mice
10:00 - 10:30 Scott Lowe  The p53 Pathway in Tumor Suppression and Cancer Therapy

10:30 - 11:00  Coffee Break

Session 11:  p53 Regulation
11:00 - 11:30  George Stark  Mutational Analysis of p53 Expression and Phosphorylation
11:30 - 12:00  Etienne Appella  Multiple Posttranslational Modifications of Human p53 Induced by DNA Damage: Coordinate Regulation, Activation of p53 and Induction of Apoptosis
12:00 - 12:30  Xin Lu  The p53 and E2F1 Connection
12:30 - 12:45  Wafik El-Deiry  Tissue-Selective Utilization of p53-Target Gene Activation During Apoptosis In Vivo

12:45 - 2:00  Lunch

Session 12:  Therapy
2:00 - 2:30  Frank McCormick  Cancer Therapy Based on the p53 Pathway
2:30 - 3:00  Andrei Gudkov  p53 as a Target for Therapeutic Suppression of p53-Dependent Drug Sensitivity in Human Colon Cancer Cells
3:00 - 3:30  Paul Hwang
3:30 - 4:00  Final Comments
2002

Barcelona

A great meeting organized by
Carlos Cordon-Cardo and
Carol Privas
New York
USA

Abstracts
The incidence of esophageal cancer in Iran and association with inflammation


1. National Research Center for Genetic Engineering and Biotechnology (NRCCEB), Tehran-Iran, (2) Tarbiat Modares University, Tehran-Iran, (3) Tehran University, Tehran-Iran, (4) Tehran University of Medical Sciences and Health Sciences, Tehran-Iran

It is recorded that the frequency of esophagitis is high (80%) in northern Iran. Esophagitis can be changed to esophageal squamous cell carcinoma. Also, it is shown that inflammation can be the cause of esophagitis. In previous study we showed that the p53 gene mutation is a frequent occurrence (64%) in esophageal squamous cell carcinoma (ESCC) from Iran. The pattern of p53 gene mutation (the Cpg transition mutation) in ESCc from Iran is high against western countries (F.Biranmijamal et al. Cancer Research April 2001). We showed that the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) correlates with p53 gene mutation in tumor cells of esophageal squamous cell carcinoma. COX-2 and iNOS are involved in inflammation.

Therefore we believe that it is possible to early detection of ESCC with examination of esophagitis biopsy sections. Also, the application of NSAIDS can be reducing the incidence of esophageal cancer in north of Iran.

Please submit your Abstract to the following address, indicating in the envelope/FAX cover letter "p53 Workshop Abstracts".

Carlos Cordon-Cardo, MD, PhD, Director, Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Tel: 212-639-7746, FAX: 212-746-1180; e-mail: cordon-ca@mskcc.org
ABSTRACT SUBMISSION

Name of Presenting Author: Dr. X
Telephone Number: xxx-xxxx

(please select one from the list below)
1. Signaling and Regulation of p53 and Mdm2
2. In vivo and in vitro Models
3. Structure/Function and Pharmacogenomics
4. Cancer Susceptibility, Molecular Epidemiology and Clinical Applications

To die or not to die, ASPP help p53 to decide

Yaelena Samuels-Lev*, Daniel J. O'Connor*, Daniele Bargamaschi*, Jiang-Kuang Hsieh, Shan Zhang, Isabelle Campagne, Giuseppe Trigiane, Louise Naumovski, Tim Crook and Xin Lu*

Ludwig Institute for Cancer Research, Imperial College School of Medicine, St. Mary's Campus, Norfolk Place, London, W2 1PG, UK

ASPP is a new family of proteins identified recently that specifically regulate the apoptotic function of p53. All members of the ASPP family interact with p53 in vivo. Co-expression of ASPP1 or ASPP2 specifically enhances the apoptotic function of p53 but not of Bax or E2F1. ASPP acts by stimulating the transactivation function of p53 specifically on the promoters of apoptosis-related genes such as Bax and PIG-3, but not on the promoters of Mdm2 and cyclin D1. Binding to p53 is necessary but not sufficient for ASPP to stimulate p53 activity. Full function of ASPP requires the intact protein. Inhibition of endogenous ASPP function by antisense RNA demonstrated that the apoptotic functions of p53 are regulated by ASPP family members in vivo in response to apoptotic stimuli. Two tumour-derived p53 mutants with reduced apoptotic function were found defective in co-operating with ASPP in apoptosis induction and Bax transactivation. A tumour-suppressor role of the p53-ASPP interaction is further supported by the observation that expression of ASPP1 and ASPP2 is frequently down-regulated in human breast carcinomas.

Although ASPP1 and ASPP2 share many structural and functional similarities, their biological functions are not redundant. All ASPP knock out mice die before weaning. Almost all the ASPP knock out mice have abnormalities in their brain and retina. The defects are detected as early as in E12.5 embryos.
Sudden panic as I've just realised that I should have sent you an abstract. I have now done this and attach the text at the end of this message. If you need to have it printed in a particular format, please let me know and I shall do this right away. My apology for the delay.

I am assuming from the information you sent out that everyone, including invited speakers, should make their own accommodation arrangements at one of the hotels listed on the Website. I shall do this imminently, but if I've misread the information and there are particular arrangements for speakers, please let me know.

Thanks for your help. See you in a few weeks.

Cheers - David

Stress-induced phosphorylation and regulation of Hdm2

David W Meek, Diane Milne, Sylvia Dias, Petros Kampanis and *Dario Alessi

Biomedical Research Centre, Ninewells Hospital and Medical School and *Medical Research Council Protein Phosphorylation Unit, University of Dundee, Dundee DD1 9SY, United Kingdom

Hdm2 plays a pivotal role as a master regulator of the p53 tumour suppressor protein and is a principal focal point of incoming stress signals which lead to p53 activation. We are studying the signalling mechanisms which impinge on Hdm2 and have detected an Hdm2 targeted protein kinase activity which is activated by high but not low doses of UV, and by camptothecin. The protein kinase phosphorylates a site close to the nuclear import/export domains of Hdm2 and bears the hallmarks of an ACG kinase, an important family of protein kinases which include protein kinase A, protein kinase B (Akt), pp90RSK and the mitogen and stress-activated protein kinase, MSK1. I shall present data on the characterisation of this protein kinase and its relationship with Hdm2.
New Zealand

A great meeting organized by Antony Braithwaite
Dunedin, New Zealand
2004

New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand
# 2004 New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION 2</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong> Moshe Oren</td>
<td></td>
</tr>
<tr>
<td>8:00am-8:30am</td>
<td>Carol Prives – Columbia University, USA</td>
</tr>
<tr>
<td></td>
<td>Regulation of the transcriptional response to p53</td>
</tr>
<tr>
<td></td>
<td>Sponsored by the University of Otago Virology Theme</td>
</tr>
<tr>
<td>8:30am-9:00am</td>
<td>Beverley Emerson – Salk Institute, USA</td>
</tr>
<tr>
<td></td>
<td>Mechanisms of stress-specific transcriptional regulation by p53</td>
</tr>
<tr>
<td>9:00am-9:30am</td>
<td>Jack Griffith – University of North Carolina, USA</td>
</tr>
<tr>
<td></td>
<td>Interaction of p53 with sites of damage and unusual DNA conformations</td>
</tr>
<tr>
<td></td>
<td>Sponsored by Children's Medical Research Institute, Sydney</td>
</tr>
<tr>
<td>9:30am-10:00am</td>
<td>Varda Rotter – The Weizmann Institute, Israel</td>
</tr>
<tr>
<td></td>
<td>Amplification of p53 induced “signature genes” in cells transformed in vitro</td>
</tr>
<tr>
<td>10:00am-10:15am</td>
<td>Shoou-Yann Shieh – Academia Sinica, Taiwan</td>
</tr>
<tr>
<td></td>
<td>p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation</td>
</tr>
<tr>
<td>10:15am-11:00am</td>
<td>Morning Tea</td>
</tr>
<tr>
<td><strong>SESSION 3</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong> Martin Levin</td>
<td></td>
</tr>
<tr>
<td>11:00am-11:30am</td>
<td>Sam Benchimol – University of Toronto, Canada</td>
</tr>
<tr>
<td></td>
<td>p63-regulated genes involved in cellular stress responses</td>
</tr>
<tr>
<td>11:30am-12:00pm</td>
<td>Amato Giocca – Stanford University, USA</td>
</tr>
<tr>
<td></td>
<td>Stress specific regulation of p53 transcriptionally dependent and independent pathways to signal apoptosis</td>
</tr>
<tr>
<td>12:00pm-12:30pm</td>
<td>Mary Helen Barcellino-Hoff – Berkeley, USA</td>
</tr>
<tr>
<td></td>
<td>Unlikely Partners: p53 and TGF-β1</td>
</tr>
<tr>
<td></td>
<td>Sponsored by Leukemia Foundation of Queensland, Brisbane</td>
</tr>
<tr>
<td>12:30pm-1:00pm</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
2004 New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand
New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand
New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand
2004 New Zealand
A great meeting organized by Antony Braithwaite
Dunedin, New Zealand

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
</table>
| 1:30pm-2:00pm | Giannino Del Sal – Laboratorio Nazionale C.I.B. Area Science Park, Italy  
*The prolyl-riomerase Pim1 acts as a fine tuner of the p53 family network*  
Sponsored by The University of Queensland, Brisbane |
| 2:00pm-2:30pm | Yoichi Taya – NCI Cancer Center Research Institute, Japan  
*A novel function of clathrin heavy chain in p53-mediated transcription and apoptosis* |
| 2:30pm-2:45pm | Kelly Harrs-McNaughton – University of Alabama, USA  
*The C terminus regulates p53 family function* |
| 2:45pm-3:00pm | Ygal Haupi – The Hebrew University Hadassah Medical School, Israel  
*Activation of p53 by PIN1 in response to DNA damage is mediated by CHK2* |
| 3:00pm-3:15pm | Luciana Giano – Mount Sinai School of Medicine, USA  
*p53 acetylation at LYS383 is required for transcriptional activation but regulates p53 stability via binding of the co-activator CBP* |
| 3:15pm-4:00pm | Afternoon Tea |
| 4:00pm-4:15pm | Laura Attardi – Stanford University School of Medicine, USA  
*Deregulating p53 function using transcriptional mutant knock-in mice* |
| 4:15pm-4:30pm | Kenneth Olive – MIT, USA  
*Tissue-specific and allele-specific effects of endogenous p53-mutant mice in mice* |
| 4:30pm-4:45pm | Anneke Blackburn – John Curtin School of Medical Research, Australia  
*Identification of novel genetic modifier hox2 for mammary tumour susceptibility in TRPSI+/- mice* |
| 4:45pm-5:00pm | Dmitry Bulavin – IMCB, Singapore  
*Tumor susceptibility and epigenetic defects in a mouse strain expressing human p53* |
| 5:00pm     | End of Conference Sessions for Day |
# 2004 New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30pm</td>
<td>Evening Activity - Kiwi Experience Night-Taieri Gorge Railway</td>
</tr>
</tbody>
</table>

**Tuesday 8th November**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
</table>
| 8:30am-8:30am | Andreas Straussner – WEHI, Australia  
*p53* and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa  
272 |
| 8:30am-9:00am | Ute Moll – State University of New York, USA  
Pro-inflammatory Macrophage Migration Inhibitory Factor (MIF) interferes with the p53 and RB-E2F pathways in a molecular link between chronic inflammation and tumorigenesis  
262 |
| 9:06am-9:30am | Maureen Murphy (T) – Fox Chase Cancer Center, USA  
p53 polymorphic variants and programmed cell death  
202a |
| 9:33am-10:00am | Doug Green – La Jolla Institute for Allergy and Immunology, USA  
PUMA couples the nuclear and cytoplasmic pro-apoptotic functions of p53  
Sponsored by The Walter and Eliza Hall Institute of Medical Research  
252 |
| 10:00am-10:15am | Silvia Soddu – Regina Elena Cancer Institute, Italy  
p53 requires activation by HAP42 to repress galectin-3 and induce apoptosis  
220 |
| 10:15am-11:06am | Morning Tea |

**SESSION 11**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
</table>
| 11:00am-11:59am | Tsukasa Shibata – University of Tokyo, Japan  
Insight into the mechanism of p53-mediated apoptosis by its target genes, Noxa and Puma  
270 |
| 11:30am-12:00pm | Xin Lu – Ludwig Institute for Cancer Research, United Kingdom  
ASPP connects ras and p53 pathways in regulating apoptosis  
261 |
| 12:00pm-12:30pm | Antony Braithwaite – University of Otago, New Zealand  
Selective impairment of p53 function by the Y-box factor VB1  
Sponsored by Invitrogen  
247 |
| 12:30pm-1:39pm | Lunch |
## 2004 New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30pm</td>
<td>Evening Activity - Kiwi Experience Night-Taieri Gorge Railway</td>
</tr>
</tbody>
</table>
| Tuesday 8th November | SESSION 10  
Chair: Carol Prives
| 8:30am-8:30am | Andreas Strasser – WQBII, Australia  
p53- and drug-induced apoptotic responses mediated by Bcl-2 only proteins Puma and Noxa  
272 |
| 8:30am-9:00am | Ute Möll – State University of New York, USA  
Pro-inflamatory Monophagocyte Migration inhibitory Factor MIF interferes with the p53 and RB-E2F pathways in a molecular link between chronic inflammation and tumorigenesis  
262 |
| 9:00am-9:30am | Maureen Murphy (1) – Fox Chase Cancer Center, USA  
p53 polymorphic variants and programmed cell death  
203a |
| 9:30am-10:00am | Doug Green – La Jolla Institute for Allergy and Immunology, USA  
PUMA couples the nuclear and cytoplasmic pro-apoptotic functions of p53  
Sponsored by The Walter and Eliza Hall Institute of Medical Research  
252 |
| 10:00am-10:15am | Silvia Roda – Regina Elena Cancer Institute, Italy  
p53 requires activation by FHIT to repress galactin-3 and induce apoptosis  
220 |
| 10:15am-11:00am | Morning Tea                                                              |
| SESSION 11 | Chair: Thea Tistie                                                        |
| 11:00am-11:30am | Tsukasa Shibata – University of Tokyo, Japan  
Insight into the mechanism of p53-mediated apoptosis by its target genes, Puma and Pumag  
270 |
| 11:30am-12:00pm | Xin Lu – Ludwig Institute for Cancer Research, United Kingdom  
ASPP connects ras and p53 pathways in regulating apoptosis  
261 |
| 12:00pm-12:30pm | Antony Braithwaite – University of Otago, New Zealand  
Selective impairment of p53 function by the Y-box factor YB1  
Sponsored by Invitrogen  
247 |
| 12:30pm-1:30pm | Lunch                                                                    |
2004 New Zealand

A great meeting organized by Antony Braithwaite

Dunedin, New Zealand
2004 New Zealand

A great meeting organized by Antony Braithwaite
Dunedin, New Zealand

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00am-9:30am</td>
<td>Barry Iacopetta — University of Western Australia</td>
</tr>
<tr>
<td>9:30am-10:00am</td>
<td>Curtis Harris — NIH/NCI, USA</td>
</tr>
<tr>
<td>10:00am-11:00am</td>
<td>Morning Tea</td>
</tr>
<tr>
<td>11:00am-11:30am</td>
<td>Mike Resnick — NIEHS/NIH, USA</td>
</tr>
<tr>
<td>11:30am-12:00pm</td>
<td>Marta Lavin — The Queensland Institute of Medical Research, Australia</td>
</tr>
<tr>
<td>12:00pm-12:15pm</td>
<td>Janice Royds — University of Otago, New Zealand</td>
</tr>
<tr>
<td>12:15pm-12:30pm</td>
<td>Arnold Levine —</td>
</tr>
<tr>
<td>12:30pm-1:30pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Close of Conference</td>
</tr>
</tbody>
</table>
2006

USA

Jill Brgonetti
Carlos Cardon-Cardo
Wei Gu
Scott Lowe
Arnold J. Levine
Jim Manfredi
Ute Moll
Carlo Privesa
On behalf of the organizing committee it is our pleasure to welcome you to the 13th International p53 Workshop here at Columbia University in New York. It is extraordinary how the p53 field continues to thrive in many areas that include molecular structure, cell and molecular biology, animal models, systems biology and translational research. This is probably the most well attended p53 workshop to date with over 350 participants from all over the world. Organizing this meeting has been both challenging and rewarding. We are particularly grateful to Louise Peterson, Inna Boluk and Sarah Kim for their unflagging assistance in helping to arrange the myriad of details that went into the preparations for the conference. Thanks are also due to members of the Prives lab, our Web Site Manager Adam Carl (with help from Cheryl Burek), Natalie Heba and the staff at the Columbia Events management office. Finally we are most indebted to our many sponsors who have provided generous financial support and without whom we could not have held this conference. This book contains the meeting agenda and speakers’ abstracts followed by abstracts of posters. General information is at the back of the book. An index has been compiled allowing you to find abstracts associated with names. We hope you will all benefit greatly from the many excellent talks and posters that will be presented and enjoy the evening events that we have planned.

Local Organizing Committee

Jill Brgonetti
Carlos Cardon-Cardo
Wei Gu
Scott Lowe
Arnold J. Levine
Jim Manfredi
Ute Moll
Carlo Privesa

International Organizing Committee

Antony Braithwaite
Curtis Harris
David Lane
Moshe Oren
Varda Rotter
Yoichi Taya
Summary Agenda for the 13th International p53 Workshop

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, May 20</td>
<td>6:30 PM</td>
<td>Opening Reception</td>
</tr>
<tr>
<td></td>
<td>8:00 PM</td>
<td>Session 1: Keynote talks</td>
</tr>
<tr>
<td>Sunday, May 21</td>
<td>8:30 AM</td>
<td>Session 2: Structure/transcription</td>
</tr>
<tr>
<td></td>
<td>11:00 AM</td>
<td>Session 3: Transcriptional regulation</td>
</tr>
<tr>
<td></td>
<td>2:00 PM</td>
<td>Session 4: Poster Session I</td>
</tr>
<tr>
<td></td>
<td>4:00 PM</td>
<td>Session 5: p53 variants</td>
</tr>
<tr>
<td>Monday, May 22</td>
<td>8:30 AM</td>
<td>Session 6: Upstream/checkpoint/regulation</td>
</tr>
<tr>
<td></td>
<td>11:00 AM</td>
<td>Session 7: Apoptosis</td>
</tr>
<tr>
<td></td>
<td>2:00 PM</td>
<td>Session 8: Poster Session II</td>
</tr>
<tr>
<td></td>
<td>4:00 PM</td>
<td>Session 9: Regulation and function of p53</td>
</tr>
<tr>
<td></td>
<td>6:30 PM</td>
<td>Depart Columbia for Boat Trip</td>
</tr>
<tr>
<td>Tuesday, May 23</td>
<td>8:30 AM</td>
<td>Session 10: Mouse Models I</td>
</tr>
<tr>
<td></td>
<td>11:00 AM</td>
<td>Session 11: Regulation and Outcomes</td>
</tr>
<tr>
<td></td>
<td>2:00 PM</td>
<td>Session 12: Mdm2 and p53</td>
</tr>
<tr>
<td></td>
<td>4:30 PM</td>
<td>Session 13: Mouse Models II</td>
</tr>
<tr>
<td></td>
<td>8:00 PM</td>
<td>Banquet</td>
</tr>
<tr>
<td>Wednesday, May 24</td>
<td>8:30 AM</td>
<td>Session 14: Translational p53 I</td>
</tr>
<tr>
<td></td>
<td>11:00 AM</td>
<td>Session 15: Translational p53 II</td>
</tr>
</tbody>
</table>

Please be aware that abstracts should not be cited in bibliographies. Material contained herein should be treated as personal communication and should be cited as such only with the consent of the author. Please note, as well, that recording of oral sessions by audio, video or still photography is prohibited except with the advance permission of the author(s), the organizers, and Columbia University.
# 2006 USA

Jill Brgonetti  
Carlos Cardon-Cardo  
Wei Gu  
Scott Lowe  
Arnold J. Levine  
Jim Manfredi  
Ute Moll  
Carlo Privesa

## Agenda for the 13th International p53 Workshop

**Saturday, May 20**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 - 6:00 PM</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Columbia University, Lerner Hall, Broadway Lobby, Broadway at 115th Street</td>
</tr>
<tr>
<td>6:30 - 8:00 PM</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>8:00 - 10:00 PM</td>
<td>Session 1</td>
</tr>
<tr>
<td></td>
<td>Keynote talks</td>
</tr>
<tr>
<td></td>
<td>Chair: C. Prives</td>
</tr>
<tr>
<td>8:00 - 8:30 PM</td>
<td>A. J. Levine MDM2 SNP309 accelerates tumor formation in a hormonally dependent manner and affects the function of p53&lt;sup&gt;ΔN143&lt;/sup&gt; in cancer. (S1)</td>
</tr>
<tr>
<td>8:30 - 9:00 PM</td>
<td>D. P. Lane Studies on the p53 system in Zebra Fish. (S2)</td>
</tr>
<tr>
<td>9:00 - 9:30 PM</td>
<td>C. Sherr The ARF tumor suppressor in hematopoietic malignancies. (S3)</td>
</tr>
<tr>
<td>9:30 - 10:00 PM</td>
<td>J. Campisi Suppression of the senescent secretory phenotype by p53. (S4)</td>
</tr>
</tbody>
</table>

**Sunday, May 21**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:30 AM</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>8:30 - 10:30 AM</td>
<td>Session 2</td>
</tr>
<tr>
<td></td>
<td>Structure/transcription</td>
</tr>
<tr>
<td></td>
<td>Chair: T. Halazonetis</td>
</tr>
<tr>
<td>8:30 - 8:55 AM</td>
<td>A. Fersht Structure and stability of p53. (S5)</td>
</tr>
<tr>
<td>9:00 - 9:10 AM</td>
<td>Z. Shakked Structural basis of DNA recognition by p53 tetramers: New insights into p53 function and regulation. (P171)</td>
</tr>
<tr>
<td>9:30 - 9:55 AM</td>
<td>R. Roeder Role of diverse co-activators in transcription regulation by p53. (S6)</td>
</tr>
<tr>
<td>10:00 - 10:25 AM</td>
<td>B. Emerson Gene specific requirement for RNA Polymerase II phosphorylation within the p53 transcriptional program. (S7)</td>
</tr>
<tr>
<td>Time</td>
<td>Session 6: Upstream/checkpoint/regulation</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>6:15 - 6:25 PM</td>
<td>J-C. Bourdon Characterization of p53 isoforms. (P18)</td>
</tr>
<tr>
<td>Evening</td>
<td>Free</td>
</tr>
<tr>
<td>Monday, May 22</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>7:30 - 8:30 AM</td>
<td>Roone Arelge Auditorium</td>
</tr>
<tr>
<td>8:30 - 10:30 AM</td>
<td>Roone Arelge Cinema</td>
</tr>
<tr>
<td>8:30 - 8:55 AM</td>
<td>T. Halazonnetis Activation of the DNA Damage checkpoint is an early event in the natural history of human cancer selecting for p53 mutations. (S15)</td>
</tr>
<tr>
<td>9:00 - 9:55 AM</td>
<td>M. Kastan Molecular controls of the ATM-p53 pathway. (S16)</td>
</tr>
<tr>
<td>9:30 - 9:55 AM</td>
<td>C. Harris Telomeric dysfunction induces p53-dependent apoptosis and senescence. (S17)</td>
</tr>
<tr>
<td>10:00 - 10:10 AM</td>
<td>S-Y Shieh The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. (P175)</td>
</tr>
<tr>
<td>10:15 - 10:25 AM</td>
<td>Y. Haupt A role for PML in the regulation of p53 by CK1. (P67)</td>
</tr>
<tr>
<td>10:30 - 11:00 AM</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00 AM - 1:00 PM</td>
<td>Roone Arelge Cinema</td>
</tr>
<tr>
<td>11:00 - 11:25 AM</td>
<td>C. Thompson Did p53 evolve to promote cell survival during nutrient deprivation? (S18)</td>
</tr>
<tr>
<td>11:30 - 11:55 AM</td>
<td>D. Green The interaction of p53, PUMA, and Bcl-xl in controlling apoptosis. (S19)</td>
</tr>
<tr>
<td>12:00 - 12:25 PM</td>
<td>S. Benchimol Determination of p53-dependent cell fate decision. (S20)</td>
</tr>
<tr>
<td>12:30 - 12:55 PM</td>
<td>J. Milner p53 and SIRT1 under non-stress conditions. (S21)</td>
</tr>
<tr>
<td>1:00 - 2:00 PM</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
2006
USA

Jill Brgonetti
Carlos Cardon-Cardo
Wei Gu
Scott Lowe
Arnold J. Levine
Jim Manfredi
Ute Moll
Carlo Privesa
2006
USA

Jill Brgonetti
Carlos Cardon-Cardo
Wei Gu
Scott Lowe
Arnold J. Levine
Jim Manfredi
Ute Moll
Carlo Privesa
2006
USA

Jill Brgonetti
Carlos Cardon-Cardo
Wei Gu
Scott Lowe
Arnold J. Levine
Jim Manfredi
Ute Moll
Carlo Privesa
2006

USA

Jill Brgonetti
Carlos Cardon-Cardo
Wei Gu
Scott Lowe
Arnold J. Levine
Jim Manfredi
Ute Moll
Carlo Privesa